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Introduction
Medical marijuana is big business. In 2016, Arizonans purchased
twenty-nine tons of cannabis products, a fifty-three percent increase
from 2015.1 Nearly 115,000 new patients registered for medical cannabis
in Arizona, a thirty percent increase over 2015.2 The state received
$29.5 million in tax revenue from medical marijuana in 2016.3 Total
marijuana sales in North America exceeded $6.7 billion in 20164 and the
estimated impact on the U.S. economy in 2020 could reach $44 billion.5
From January 1, 2017 through October 13, 2017, $1.9 billion of new
capital was raised and invested in the cannabis industry.6
Big business typically sparks big litigation, but medical marijuana
and products liability have been virtual strangers. They will not be for
long. While only two cannabis products liability cases have been filed
in the United States to date (both in Colorado),7 it is easy to envision
dozens, if not hundreds, of cases being filed in the next decade. This
paper considers the basis for potential claims and the actions the
industry can take now to increase patient safety and mitigate liability.
1.

Eli McVey, Arizona Medical Marijuana Patient Count in 2016,
MARIJUANA BUS. DAILY (Feb. 6, 2017), mjbizdaily.com%2Fchart-arizonagrowing-intomedical-marijuana-juggernaut%2F.

2.

Eli McVey, Arizona Growing into Medical Marijuana Juggernaut,
MARIJUANA BUS. DAILY (Feb. 06, 2017), http://mjbizdaily.com/chartarizona-growing-into-medical-marijuana-juggernaut.

3.

Ray Stern, Arizona Medical Marijuana Sales Hit Record High: We Bought
29 Tons in ‘16, State Got $29.5 Million in Taxes, PHOENIX NEW TIMES
(Jan. 24, 2017), https://www.phoenixnewtimes.com/news/arizonamedical-marijuana-sales-hit-record-high-we-bought-29-tons-in-16-stategot 295-million-in-taxes-9018620.

4.

Debra Borchardt, Marijuana Sales Totaled $6.7 Billion in 2016, FORBES
(Jan. 3, 2017, 9:00 AM), https://www.forbes.com/sites/debraborchardt
/2017/01/03/marijuana00000-sales-totaled-6-7-billion-in-2016/
#2ca7610a75e3.

5.

David Schepp, Legal Marijuana: A $44 Billion Business by 2020?, CBS
MONEYWATCH (Mar. 18, 2016, 5:30 AM), https:// www.cbsnews.com
/news/legal-marijuana-a-44-billion-business-by-2020/.

6.

Cannabis Deal Tracker: Investment and M&A Activity in the Cannabis
Industry, VIRIDIAN CAPITAL ADVISORS, http://mailchi.mp/viridianca
/deal-tracker-2930261 (last visited Sep. 29, 2018).

7.

See, e.g. Compl. at 2, Flores v. Livwell Inc. (D. Colo. 2015) (No.
2015CV33528); Am. compl. at 7, Kirk v. Nutritional Elements, Inc. (D.
Colo.) (No. 16CV31310).
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Part I discusses basic information about medical marijuana and its
supply chain of production. Part II explores current federal and state
law. Part III suggests a paradigm for medical marijuana liability.
Potential regulation for medical marijuana is explored by comparison
to similar products that are subject to varying regulations. Part IV
describes our current knowledge of the therapeutic and adverse effects
of medical marijuana. It also highlights that more research is needed to
fully understand and educate users about the risks and benefits of
medical marijuana. Part V considers manufacturing defects as a theory
of product liability. Part VI discusses defective design related to the
unregulated nature of medical cannabis, while Part VII explores the
current system’s failure to warn. Finally, Part VIII examines the special
problem of youth marketing.

I. The Basics
A.

Marijuana

Marijuana is a plant, more specifically a greenish-gray mixture of
dried flowers from Cannabis sativa.8 It is referred to by a wide variety
of names, including cannabis, weed, herb, pot, grass, bud, ganja, 420,
and Mary Jane.9 Individuals and corporations on the cutting edge of
the marijuana industry are called “ganjapreneurs.”10
Marijuana is used for both recreational and medical purposes.11 This
article focuses on medical marijuana, particularly in edible form.
According to the National Institute on Drug Abuse, a division of
National Institutes of Health (NIH), “medical marijuana refers to using
the whole, unprocessed marijuana plant or its basic extracts to treat
symptoms of illness and other conditions.”12 Web MD defines medical
marijuana as “the use of this drug to help treat symptoms like pain,
muscle stiffness (spasticity), nausea, and lack of appetite. It may be
used by people who have conditions like cancer, AIDS, or multiple
8.

Marijuana as Medicine, NIH NAT’L INST. ON DRUG ABUSE,
https://www.drugabuse.gov/publications/drugfacts/marijuana-medicine
(last updated June 2018).

9.

What is Marijuana?, NIH - NAT’L INST. ON DRUG ABUSE, https://
www.drugabuse.gov/publications/research-reports/marijuana/whatmarijuana (last updated June 2018).

10.

Madhura Yale, Cash in on Marijuana Boom: Become a Ganjapreneur,
JUNGLEWORKS, https://jungleworks.com/cash- marijuana-boom-becomeganjapreneur (last visited Dec. 19, 2018).

11.

NAT’L ACAD. SCIENCES, ENG’G, & MED., THE HEALTH EFFECTS OF
CANNABIS AND CANNABINOIDS: THE CURRENT STATE OF EVIDENCE AND
RECOMMENDATIONS FOR RESEARCH, xvii, 1 (Nat’l Acad. Press eds., 2017),
available at https://www.nap.edu/catalog/24625/the-health-effects-ofcannabis-and-cannabinoids-the-current-state.

12.

Marijuana as Medicine, supra note 8.
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sclerosis.”13 The working definition of medical cannabis for the purposes
of this article is: the use of one or more components of the Cannabis
sativa plant, as recommended by a licensed healthcare provider, for the
treatment of a disease or its symptoms.
Cannabis sativa is a complex substance, containing 545
constituents.14 The most significant medicinal components are the
psychoactive delta-9-trans-tetrahydrocannabinol (THC) and the nonpsychoactive cannabidiol (CBD).15 Both compounds exert effects on the
ubiquitous endocannabinoid system.16
The endocannabinoid system is a highly complex, endogenous
system in the human body.17 For the purposes of this article, the two
most important cannabinoid receptors are CB1 and CB2. The
distribution of these receptors in various tissues accounts for the
psychotropic and peripheral effects of THC.18 CB1 receptors are most
abundant in the basal ganglia, cerebellum, hippocampus, and cerebral
cortex.19 CB2 receptors are most commonly found in immune cells and
tissues.20 By activating CB1 receptors, THC affects high-order
behavioral activities, such as executive functioning, decision making,
sensory responsiveness, motor function, learning, memory, and
emotional reactions.21 Short term effects of THC on the central nervous
system (CNS) are dose-dependent and include:22

13.

14.

Medical Marijuana FAQ, WEBMD, http://www.webmd.com/mentalhealth/tc/medical-marijuana-topic-overview#1 (last visited Oct. 11,
2017).
MAHMOUD ELSOHLY & WASEEM GUL, CONSTITUENTS OF CANNABIS SATIVA
HANDBOOK OF CANNABIS, 3 (Roger G. Pertwee ed., 2014).

IN

15.

Carola Rong et al., Cannabidiol in Medical Marijuana: Research Vistas
and Potential Opportunities, 121 PHARMACOLOGICAL RESEARCH 213, 214
(2017).

16.

Id.

17.

Id.

18.

See Vincenzo Di Marzo et al., The Endocannabinoid System and its
Therapeutic Exploitation, 3 NAT’L REV. DRUG DISCOVERY 771, 772 (2004).

19.

See Debra A. Kendall et al., Cannabinoid Receptors in the Central
Nervous System: Their Signaling and Roles in Disease, 10 FRONTIERS IN
CELLULAR NEUROSCIENCE 1, 1(2017).

20.

Id. at 3.

21.

Bradley E. Alger, Getting High on the Endocannabinoid System,
CEREBRUM at 4 (Nov. 1. 2013), available at https://www.ncbi.nlm.nih.gov
/pmc/articles/PMC3997295/.

22.

Marijuana as Medicine, supra note 8.
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altered senses and perception



distorted sense of time



mood fluctuations



impaired body movement



disorganized thinking and problem-solving



diminished memory



hallucinations



delusions



psychosis

The effects of CBD are less well understood. CBD interacts with
multiple receptors in the endocannabinoid system, antagonizing CB1
receptors but potentiating CB2 receptors.23 In contrast to THC, CBD
has salutary effects on mood, anxiety, and sleep disturbances.24
Cannabis can be smoked, vaporized, brewed, and ingested in foods
and drinks.25 Administration of cannabis produces a blood level of all
545 constituent compounds;26 however, therapeutic effects and adverse
reactions differ based on the method of administration.27 Ingested
components, known as edibles, have variable pharmacodynamics. Their
effects and side effects are uncertain.28 Consequently, the
unpredictability of their effects and the resulting enhanced potential for
harm suggests that edibles are likely to precipitate the bulk of medical
marijuana products liability and litigation. Thus, edibles will be the
focus of this article.
Marijuana edibles are food items infused with cannabis or its
concentrates. They contain cannabinoids and are popular alternatives

23.

Rong et al., supra note 15, at 213-214.

24.

Rong et al., supra note 15, at 215.

25.

NAT’L ACAD. SCIENCES, ENG’G, & MED., supra note 11, at 50.

26.

Ron R. Flegel, SAMHSA’S Role: Integrating the Science & Technical
Information into Regulated Testing, AM. SOC. ADDICTION MED. (Oct. 07,
2016), available at https://www.asam.org/docs/default-source/educationdocs/state-of-the-art-2016/session-6- combined.pdf.

27.

NAT’L ACAD. SCIENCES, ENG’G, & MED., supra note 11, at 51.

28.

Noelle Crombie, How Potent Are Marijuana Edibles? Lab Tests Yield
Surprising
Results,
MARIJUANA
NEWS
(Mar.
06,
2015),
https://www.oregonlive.com/marijuana/index.ssf/2015/03/how_potent
_are_marijuana_edibl.html.
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to smoking or vaporizing cannabis.29 Edibles became popular after Alice
B. Toklas created and published a recipe for Hashish Fudge in her 1954
cookbook.30 The recipe was published in the British edition but omitted
from the U.S. edition until the second publishing in the early 1960’s.31
The craze was popularized by the movie, I Love You, Alice B. Toklas,
in which the conservative Peter Sellers was introduced to hash brownies
by a hippie.32 Edibles come in many forms, often reminiscent of products
found in a supermarket, candy store, or bakery. Here is a partial list:


Beverages – soda, tea, coffee, beer, lemonade, smoothies



Breakfast – rice crispy cereal bars, fruit and nut snacks,
breakfast bars, croissants, madeleines, and oat squares



Brownies



Candy – gummy worms, gummy bears, caramels, sour drops,
dried pineapple, fruit chews, mints, jellies, caramel popcorn,
pastilles, coconut almond candy bars, apple rings, lollipops,
lozenges, taffy, gourmet fruit slices, lemon drops, and peanut
butter bars



Chocolates – white, milk and dark bars (plain, raisins, nuts,
peanut butter, or caramel) and peppermint patties



Condiments – honey, BBQ sauce, blue cheese dressing, ranch
dressing, jelly, maple syrup, and peanut butter



Cookies – snickerdoodle, ginger snap, chocolate, oatmeal,
butterscotch, sugar, mint, coconut, peppermint, molasses,
lemon, peanut butter, red velvet, and gluten-free



Cooking – butter, olive oil, vegetable oil, coconut oil, honey,
vinaigrette, marinades

29.

See Daniel Barrus et al., Tasty THC: Promises and Challenges of
Cannabis Edibles, RTI INT’L (Nov. 2016), https://www.rti.org/rti-presspublication/tasty-thc.

30.

Dave Chachere, Alice in Wonderland: The Toklas Brownie, DOPE
MAGAZINE (Nov. 28, 2016), https://www.dopemagazine.com/alicewonderland-toklas-brownie/.

31.

Layla Eplett, Go Ask Alice: The History of Toklas’ Legendary Hashish
Fudge, SCI. AM. (Apr. 20, 2015), https://blogs.scientificamerican.com
/food-matters/go-ask-alice-the-history-of-toklas-8217-legendary-hashishfudge/.

32.

Id.
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Snacks – rice crispy treats, bars, crackers, fish crackers,
cupcakes, pies, baklava, macaroons, peanut butter cups, and
mixed nut clusters.33
B.

Supply Chain

According to the online Business Dictionary, a supply chain consists
of a network of entities, directly or indirectly interlinked and
interdependent, which serve the same consumer or customer.34 The
supply chain includes raw material vendors, manufacturers,
warehouses, distribution centers, and retailers. The three basic
functions of a supply chain are the: (1) supply of raw materials to a
manufacturer; (2) actual manufacturing; and (3) delivery of the finished
product via a network of distributors and retailers to the end user.35
Regarding medical marijuana, the supply chain can be
diagrammatically represented as follows:
Cultivation → Extraction → Distribution → Retail → Patient
↕
↑
Testing
Physician

Figure 1. Supply Chain Schematic

Growers plant and harvest the cannabis crop. Buds, or flowers, are
separated from the plant and processed.36 Manufacturers produce
cannabis-infused edibles, oils, waxes, and tinctures.37 Extractions and
final products undergo laboratory testing for purity and THC

33.

LEAFLY, https://www.leafly.com/products/edibles (last visited Sept. 30,
2018).

34.

BUSINESS DICTIONARY, http://www.businessdictionary.com/ (last visited
Sept. 27, 2018).

35.

See Cannabis Supply Chain Traceability, GITHUB (Mar. 23, 2016),
https://github.com/CannabisReports/Cannabis-Supply-ChainTraceability/blob/master/cannabis-supply-chain-traceability.md; Supply
Chain Definitions, CANADIAN SUPPLY CHAIN SECTOR COUNCIL,
http://www.supplychaincanada.org/en/supply-chain (last visited Sept.
23, 2018).

36.

See Arizona Cannabis Society Grower Job Description, OAKSTERDAM
UNIVERSITY,
https://oaksterdamuniversity.com/wp-content/uploads/
2017/10/Arizona-Cannabis-Society-Grower-Job-Description.pdf
(last
visited Sept. 30, 2018); See Max Anderson, Best Tips For Harvesting
Cannabis,
PROD.
GROWER
(March
11,
2018),
https://
productiongrower.com/blogs/how-to-grow-weed/harvesting; See Your
Guide to Drying and Curing Cannabis Buds, LEAFLY (Aug. 8, 2016),
https://productiongrower.com/blogs/how-to-grow-weed/harvesting.

37.

Market
Opportunity,
BUDLIFE,
https://www.budlife.net/medicalmarijuana-1/ (last visited Sept. 27, 2018).
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concentration.38 Physicians evaluate patients for medical marijuana
program qualifying characteristics.39 Qualifying patients receive
certifications and are directed to retail dispensaries that sell the finished
products.40

II. Federal and State Medical Marijuana Law
A.

Federal Marijuana Law

Marijuana is currently illegal under federal law.41 The U.S. Drug
Enforcement Agency (DEA) classifies cannabis as a Schedule I drug.42
“Schedule I drugs, substances, or chemicals are defined as drugs with
no currently accepted medical use and a high potential for abuse.”43
Other Schedule I drugs include heroin, lysergic acid diethylamide
(LSD), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone
(Quaalude), and peyote.44 Further, the DEA claims there is “a lack of
accepted safety for use of the drug or other substance under medical
supervision.”45
On July 19, 2016, the DEA denied a petition to initiate rulemaking
proceedings to reschedule marijuana to a classification where it could
be used medicinally.46 Their conclusion was based on their consistent
findings that marijuana: (1) “has a high potential for abuse;” (2) “has
no currently accepted medical use in treatment in the United States;”
and (3) “lacks accepted safety for use under medical supervision.”47

38.

See What You Need to Know About Cannabis Testing, Lab Setup and
Training, GENIE SCI., https://www.geniescientific.com/what-you-need-toknow-about-cannabis-testing-lab-setup-and-training (last visited Sept. 27,
2018).

39.

Qualifying Conditions for a Medical Marijuana Card by State, LEAFLY
(Oct.
30,
2017),
https://www.leafly.com/news/health/qualifyingconditions -for-medical-marijuana-by-state.

40.

Jeremiah Wilhelm, Understanding Medical vs. Adult-Use Cannabis
Dispensaries, LEAFLY (Jan. 30, 2017, 1:58 PM), https://www.leafly
.com/news/cannabis-101/what-is-a-marijuana-dispensary/print/.

41.

21 U.S.C. § 812(b)(1) (2012).

42.

Drug Scheduling, U.S. DRUG ENF’T ADMIN., https://www.dea.gov/
druginfo/ds.shtml (last visited Oct. 11, 2017).

43.

Id.

44.

Id.

45.

U.S. DRUG ENF’T ADMIN., DRUGS OF ABUSE: A DEA RESOURCE GUIDE
(2017), available at https://www.dea.gov/documents/2017/06/15/drugsabuse.

46.

Denial of Petition to Initiate Proceedings to Reschedule Marijuana, 18
Fed. Reg. 53767 (Aug. 12, 2016).

47.

Id.
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Although cannabis is illegal under federal law, enforcement of those
laws was guided by the 2013 Cole Memorandum entitled, “Guidance
Regarding Marijuana Enforcement.”48 This memorandum shifted
governmental priorities from tough enforcement of federal cannabis law
towards a more hands-off approach in those “jurisdictions that have
enacted laws legalizing marijuana in some form and that have also
implemented strong and effective regulatory and enforcement systems
to control the cultivation, distribution, sale and possession of
marijuana.”49 Further, the Cole Memorandum declared that:
a robust system may affirmatively address [federal] priorities by,
for example, implementing effective measures to prevent diversion
of marijuana outside the regulated system and to other states,
prohibiting access to marijuana by minors, and replacing an illicit
marijuana trade that funds criminal enterprises with a tightly
regulated market in which revenues are tracked and accounted
for.50

The relaxed attitude of the Obama Administration did not survive
past the first year of the Trump presidency. On January 4, 2018,
Attorney General Jefferson B. Sessions, III drafted a memorandum to
all U.S. Attorneys rescinding the Cole Memorandum and other federal
guidelines that circumscribed the prosecution of individuals and entities
following state law in the use and sale of marijuana.51 Federal
prosecutors have been instructed to decide which cases to prosecute
based on “federal law enforcement priorities set by the Attorney
General, the seriousness of the crime, the deterrent effect of the criminal
prosecution, and the cumulative impact of particular crimes of the
community.”52
B.

State Marijuana Law

According to the National Conference of State Legislatures, as of
2018, thirty-three states plus the District of Columbia, Guam, and
Puerto Rico have enacted laws permitting the medical use of

48.

DEPUTY ATT’Y GEN. JAMES M. COLE, MEMORANDUM FOR ALL UNITED
STATES ATTORNEYS: GUIDANCE REGARDING MARIJUANA ENFORCEMENT,
Aug. 29, 2013), available at https://www.justice.gov/iso/opa/
resources/3052013829132756857467.pdf.

49.

Id.

50.

Id.

51.

Id.

52.

Id.
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marijuana.53 States that have legalized medical marijuana are
predominantly in the west, southwest, northeast, and northwest.54
The Arizona Medical Marijuana Act (AMMA), captioned as A.R.S.
§§ 36-2801 to -2819, was passed as Proposition 203 in 2010.55 The law
permits the certification of individuals with a “debilitating medical
condition” for medical marijuana use.56 Debilitating conditions include
the following:
(a)
Cancer,
glaucoma,
positive
status
for
human
immunodeficiency virus (HIV), acquired immune deficiency
syndrome (AIDS), hepatitis C, amyotrophic lateral sclerosis,
crohn’s disease, agitation of alzheimer’s disease or the treatment
of these conditions.57
(b) A chronic or debilitating disease or medical condition or its
treatment that produces one or more of the following: cachexia or
wasting syndrome; severe and chronic pain; severe nausea;
seizures, including those characteristic of epilepsy; or severe and
persistent muscle spasms, including those characteristic of
multiple sclerosis.
(c) Any other medical condition or its treatment added by the
department pursuant to section 36-2801.01.58

Qualifying patients are certified for medical use of marijuana by
actively licensed allopathic, osteopathic, naturopathic, or homeopathic
physicians in Arizona.59 Physicians do not “prescribe” marijuana
because that would violate federal law.60 Instead, physicians
53.

Jeremy Berke & Skye Gould, This Map Shows Every US State Where Pot
is Legal, BUS. INSIDER (Jan. 4, 2019), https://www.businessinsider.com
/legal-marijuana-states-2018-1.

54.

See Marijuana DeepDive, NAT’L CONF. ST. LEGIS., http://www.ncsl.org
/bookstore/state-legislatures- magazine/marijuana-deep-dive.aspx (last
visited Jan. 27, 2018).

55.

Ariz. Rev. Stat. Ann. § 36-2801(18) (2010).

56.

Id.

57.

The Arizona legislature left out the capital letters of the diseases
characterized by and named after Alois Alzheimer, M.D. and Burrill
Crohn, M.D. Ariz. Rev. Stat. Ann. § 36-2801(3) (2010).

58.

Debilitating conditions are subject to change annually via petition to the
state health department. Id.; See e.g., Petition to Add a Debilitating
Condition, COLO. DEP’T PUB. HEALTH & ENV’T, https://
www.colorado.gov/pacific/cdphe/petition-to-add-debilitating-condition
(last visited Dec. 18, 2018).

59.

Ariz. Rev. Stat. Ann. §§ 36-2801(12), (13) (2018).

60.

TODD GARVEY ET AL., CONG. RESEARCH SERV., R43435, MARIJUANA:
MEDICAL AND RETAIL – SELECTED LEGAL ISSUES at 4 (2015).
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“recommend” marijuana and certify in writing that they believe the
patient is likely to “receive therapeutic or palliative benefit from the
medical use of marijuana to treat or alleviate the patient’s debilitating
medical condition or symptoms associated with the debilitating
condition.”61 The physician’s right to recommend marijuana has been
held to be protected by the First Amendment.62

III. Medical Marijuana as a “Pharma-pseudical”
States considering the legalization of medical marijuana must
consider the paradigm under which it will be regulated. This is
complicated by the fact that, in many ways, medical marijuana is a
unique product because it is used for both recreation and medical
purposes. Medical cannabis is “recommended” by doctors, but never
prescribed. It is rarely dispensed by a pharmacist, but rather by a
retailer with no mandatory training or certification.63 Thus, medical
cannabis has some characteristics in common with alcohol, tobacco,
nutritional supplements, and pharmaceuticals. Medical marijuana most
closely resembles a pharmaceutical; though important differences exist.
For that reason, the term, “pharma-pseudical,” shall be used to indicate
medical marijuana is akin to a pseudo-pharmaceutical.
A.

Alcohol

Although there are similarities, there are three reasons why alcohol
is not a useful heuristic for marijuana regulation. First, while alcohol
and marijuana have intoxicating effects with oral or intravenous
administration, there is no currently recognized medical indication for
the internal use of alcohol.64 Once used internally as an anesthetic and

61.

Ariz. Rev. Stat. Ann. § 36-2801(12).

62.

Conant v. Walters, 309 F.3d 629, 638-39 (9th Cir. 2002) (affirming district
court’s permanent injunction enjoining federal government from revoking
DEA registration or investigating physician in a manner that might lead
to revocation where the government’s action based solely on physician’s
recommendation of medical marijuana. Doctor’s speech to patient
protected under First Amendment).

63.

State Medical Marijuana Legislation and the Pharmacist’s Role, NAT’L
CMTY. PHARMACISTS ASS’N, http://www.ncpa.co/pdf/medical-marijuanaone-pager-aug-2017.pdf (last visited Dec. 18, 2018).

64.

Alcohol, If You Drink it, Keep it Moderate, MAYO CLINIC,
https://www.mayoclinic.org/healthy-lifestyle/nutrition-and-healthyeating/in-depth/alcohol/art-20044551 (last updated Nov. 6, 2018);
Resveratrol, a component of the skins of red grapes has a limited
antioxidant and anti-inflammatory effect. Evidence of its benefits is
minimal. Chandra K. Sing, et al., Resveratrol, in its Natural Combination
in Whole Grape, for Health Promotion and Disease Management, 1348
ANNALS N.Y. ACAD. SCI. 150, 151 (2015).
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as a tocolytic in the mid-twentieth century, 65 alcohol is currently
indicated only externally as an antiseptic and disinfectant.66
Second, ethyl alcohol is regulated by a complex network of federal,
state, and municipal statutes and rules.67 Medical marijuana is
regulated by state law68 and issues of zoning are municipal.69 Third,
because the dangers of alcohol are readily apparent and universally
known, manufacturers of alcoholic beverages have a very limited duty
to warn consumers.70 Beverages containing more than 0.5% of alcohol
by volume are required to have only two warnings: “(1) According to
the Surgeon General, women should not drink alcoholic beverages
during pregnancy because of the risk of birth defects. (2) Consumption

65.

Tocolytic drugs are used to stop preterm labor. The current drug of choice
is terbutaline. J.D. Whitby, Alcohol in Anaesthesia and Surgical
Resuscitation, 35 ANAESTHESIA 502, 502 (1980); Marc J.N.C. Keirse, The
History of Tocolysis, 110 BRITISH J. OBSTETRICS AND GYNAECOLOGY 94,
95 (2003).

66.

Ethyl alcohol has been taken internally; isopropyl alcohol is used
externally. See Gerald McDonnell & A. Denver Russell, Antiseptics and
Disinfectants: Activity, Action, and Resistance, 12 CLINICAL
MICROBIOLOGY REV. 147, 148-151 (1999).

67.

See e.g., 26 U.S.C. §5601(a)(8) (2006); VA. CODE ANN. §§ 4.1-100, 4.1302; LAKEWOOD, COLO. MUN. CODE § 9.41.070 (2015).

68.

See Gina K. Grimes & Morris C. Massey, Medical Marijuana –
Differences Among States’ Regulatory Frameworks and Land Use and
Zoning Regulation, 29 PROBATE & PROPERTY MAGAZINE (Nov. 2015),
available at https://www.americanbar.org/groups/real_property_trust_
estate/publications/probate_property_magazine_home/2015/november
_de
cember_2015/2015_aba_rpte_pp_v29_6_article_grimes_massey_me
dical_marijuana_differences_among_states.html.

69.

Robert Careless, Zoning Hurdles for Budding Pennsylvania Cannabis
Businesses, THE TEMPLE 10-Q (Oct. 27, 2017), https://www2.law.
temple.edu/10q/zoning-hurdles-budding-pennsylvania-cannabisbusinesses/.

70.

After Abernathy died of acute alcohol intoxication, his estate sued
whiskey distiller, Schenley, for failure to warn of the hazards of acute
intoxication. The Fourth Circuit Court of Appeals held that fulfilling the
statutory labeling obligations was sufficient to eschew liability. See
Abernathy v. Schenley Industries, Inc., 556 F.2d 242, 243 (4th Cir. 1977)
(holding that fulfilling statutory labeling obligations was sufficient to
eschew liability). Garrison sued Heublein, manufacturer and distributor
of Smirnoff Vodka, under a failure to warn theory for mental and physical
injuries arising from two decades of heavy vodka consumption. Adopting
Restatement (Second) of Torts § 402A as Illinois law, the court dismissed
the case, holding that the dangers of alcohol were common knowledge,
and the product was not unreasonably unsafe. See Garrison v. Heublein,
Inc., 673 F.2d 189 (7th Cir. 1982).

236

Health Matrix·Volume 29·Issue 1·2019
High Times Ahead: Products Liability in Medical Marijuana

of alcoholic beverages impairs your ability to drive a car or operate
machinery, and may cause health problems.” 71
B.

Tobacco

Tobacco is also a poor choice as a paradigm for medical marijuana
regulation. Tobacco has no recognized medicinal use.72 It is permitted,
but regulated by numerous federal, state, and local laws.73 Marijuana is
not regulated by any federal laws, only prohibited.74 Severe, adverse
health effects are widely recognized, in part due to the ubiquitous
warning labels on each cigarette pack.75 Since 1984, cigarette
manufacturers have been required to display on each pack of cigarettes
one of four health warning labels on a quarterly rotating basis:76

Figure 2. Cigarette Warning Labels

C.

Nutritional Supplements

Nutritional supplements and medical marijuana are both promoted
for their salutary effects,77 although compelling scientific evidence of the

71.

27 C.F.R. § 16.21 (1990).

72.

John Harvey Kellog, Tobaccoism, 92 AM. J. PUB. HEALTH 932, 932 (2002).

73.

Local Tobacco Regulation, RJREYNOLDS, https://www.rjrt.com/
commercial-integrity/state-local-regulation/ (last visited Sept. 21, 2018).

74.

Donna Leinwand Leger, Marijuana to Remain Illegal Under Federal Law,
DEA
Says,
USA
TODAY
(Aug.
11,
2016,
5:54
PM),
https://www.usatoday.com/story/news/2016/08/11/dea-marijuanaremains-illegal-under-federal-law/88550804/.

75.

15 U.S.C. § 1333(a)(1) (2010).

76.

Making
Decisions
Regarding
Tobacco
Use,
RJREYNOLDS,
http://www.rjrt.com/tobacco-use-health/public-health-information/
(last visited Oct. 14, 2018).

77.

Dietary Supplements: What you Need to Know, NIH - NAT’L INST.
HEALTH,
https://ods.od.nih.gov/HealthInformation/DS_WhatYouNeedToKnow.a
spx (last updated June 17, 2011); Peter Grinspoon, Medical Marijuana,
HARV. HEALTH PUB. (Jan. 15, 2018), https://www.health.harvard.edu
/blog/medical- marijuana-2018011513085.
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benefits of supplements is lacking.78 Supplements are federally regulated
by the Food and Drug Administration (FDA) under the Dietary
Supplement Health and Education Act of 1994;79 however, the FDA
does not evaluate dietary supplements for effectiveness and safety in
the premarketing phase.80 The FDA is only authorized to restrict the
sale of misbranded or adulterated dietary supplements in the
marketplace.81
While the FDA does not currently regulate medical marijuana, that
may change soon. On October 3, 2017, the FDA Commissioner, Scott
Gottlieb, indicated that the agency would investigate dubious health
claims made by marijuana producers, especially anti-tumor/anti-cancer
effects of THC.82
With rare exceptions, dietary supplements have no psychoactive
effects and are not recommended for the treatment of any condition or
disease in traditional modern medicine.83 Most supplements are required
to have a disclaimer that any claims of benefit have not been evaluated
by the FDA.84 They may be recommended by some physicians,
especially those practicing alternative medicine, but prescriptions and
certifications are not required.85
D.

Pharmaceuticals

Medical marijuana is most closely related to pharmaceuticals.
Cannabis has specific medical indications defined by statute while

78.

Should You Take Dietary Supplements?, NIH NEWS IN HEALTH (Aug.
2013),
https://newsinhealth.nih.gov/2013/08/should-you-take-dietarysupplements.

79.

Dietary Supplements, U.S. FOOD & DRUG ADMIN., https://www.fda.gov
/food/dietarysupplements/ (last updated Nov. 16, 2018).

80.

See Id.

81.

Id.

82.

FDA and Marijuana, U.S. FOOD & DRUG ADMIN., https://www.fda.gov
/NewsEvents/PublicHealthFocus/ucm421163.htm (last updated June 25,
2018).

83.

NIH NEWS IN HEALTH, supra note 78.

84.

Understanding the Claims on Dietary Supplement Labels, AM. CANCER
SOC.,
https://www.cancer.org/treatment/treatments-and-side-effects/
complementary-and-alternative-medicine/dietary-supplements/readinglabels.html (last updated Mar. 31, 2015); Questions and Answers on
Dietary Supplements, U.S. FOOD & DRUG ADMIN., https://www.
fda.gov/Food/DietarySupplements/UsingDietarySupplements/ucm48006
9.htm. (last updated Jun. 19, 2018).

85.

Where Can I Purchase Dietary Supplements?, NAT’L INST. HEALTH,
https://ods.od.nih.gov/Health_Information/ODS_Frequently_Asked_
Questions.aspx, (last updated July 1, 2013).
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medications have specific medical indications defined by the FDA.86 A
patient can only obtain medical cannabis if it has been recommended
by a physician and can only obtain many pharmaceuticals if they have
been prescribed by a physician. Prior to patient certification for medical
cannabis, in some states a physician must perform a medical history
and physical examination, review prior medical records, and weigh the
risks and benefits of medical marijuana for the particular patient.87 This
process closely resembles traditional medical practice with
pharmaceuticals.
Perhaps, the most persuasive reason for comparing medical
marijuana and pharmaceuticals is that plant-derived THC is identical
to the drug, Marinol (dronabinol).88 Marinol is a synthetic version of
THC,89 with important similarities. Marinol is a Schedule III90
controlled substance indicated for the treatment of AIDS-related
anorexia associated with weight loss, as well as chemotherapy-induced
nausea and vomiting when standard antiemetics are ineffective.91
Marinol users are warned against operating a motor vehicle and heavy
machinery or engaging in other hazardous activities.92 Oral dosages
range from 2.5 milligrams to 20.0 milligrams per day.93 Multiple drug
interactions have been reported, most commonly with antidepressants,
antihistamines, benzodiazepines, and barbiturates.94
From the products liability perspective, one of the most important
questions is whether the Learned Intermediary Doctrine will apply to
medical cannabis as it does to pharmaceuticals. If the doctrine applies
to both, much of the liability from harm related to medical marijuana
will be redirected from the participants in the supply chain to the
physicians.

86.

Omudhome Ogbru, Indications for Drugs (Uses), Approved vs. Non(Aug.
20,
2015),
https://www.
Approved,
MEDICINENET
medicinenet.com/indications_for_drugs__approved_vs_nonapproved/views.htm.

87.

The Role of the Physician in “Medical” Marijuana, AM. SOC’Y ADDICTION
MED. 20-21 (2010), available at https://www.asam.org/docs/publicypolicy-statements/1role_of_phys_in_med_mj_9-10.pdf?sfvrsn=0.

88.

U.S. FOOD & DRUG ADMIN., NDA 18-651/S-021, MARINOL (2004).

89.

ALISON MACK & JANET JOY, MARIJUANA AS MEDICINE? 142 (2001).

90.

A Schedule III drug has “a moderate to low potential for physical and
psychological dependence.” Drug Scheduling, supra note 42.

91.

MACK & JOY, supra note 89 at 8.

92.

FOOD & DRUG ADMIN., REFERENCE ID: 4145204, FULL PRESCRIBING
INFORMATION: MARINOL (2017).

93.

U.S. FOOD & DRUG ADMIN., NDA 18-651/S-025
(2004).

94.

Id.
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The Learned Intermediary Doctrine limits a manufacturer’s duty
to warn about the potential adverse consequences of a pharmaceutical
or medical device to the prescribing physician and not the patient.95 For
example, in Toole v. McClintock, the adequacy of the manufacturer’s
warning about the hazards of its breast implant was based solely on the
efficacy of the warning to the patient’s physician.96 The court held that
the manufacturer had no duty to warn the patient.97
Notwithstanding the Learned Intermediary Doctrine, some courts
have implicitly or explicitly held that a manufacturer has a duty to
directly warn patients of the potential hazards of their drugs or medical
devices.98 Three exceptions to the Doctrine have been carved out: (1)
warnings to parents of minor children;99 (2) direct marketing of drugs
to consumers;100 and (3) treatment decisions driven predominantly by
patient choice with minimal physician input.101
The applicability of the Learned Intermediary Doctrine to medical
cannabis is uncertain. The following reasons illustrate why it is likely
that the Learned Intermediary Doctrine will not apply and participants
in the cannabis supply chain will bear the majority of the liability for
harms suffered by patients. Most medical marijuana evaluations are
performed at “specialty” medical marijuana clinics that have only one
purpose - to ascertain whether a patient is a suitable candidate for

95.

Hill v. Wyeth, Inc., No. 4:03CV1526 JCH, 2007 WL 674251 (E.D. Mo.
Feb. 28, 2007).

96.

Toole v. McClintock, 999 F.2d 1430, 1436 (11th Cir. 1993).

97.

Id. at 1433.

98.

See e.g., Reyes v. Wyeth Lab., 498 F.2d 1264, 1274 (5th Cir. 1974); Perez
v. Wyeth Lab., 734 A.2d 1245, 1247 (N.J. 1999); McDonald v. Ortho
Pharm. Co., 475 N.E.2d 65, 68 (Mass. 1985).

99.

Reyes v. Wyeth Laboratories, 498 F.2d 1264, 1279 (5th Cir. 1974).

100. In a case involving the subdermal insertion of the contraceptive, Norplant,
the Supreme Court of New Jersey opined “that the learned intermediary
doctrine does not apply to the direct marketing of drugs to consumers
. . . .” Perez v. Wyeth Laboratories, 734 A.2d 1245, 1257 (N.J. Sup. Ct.
1999). Plaintiffs argued that Norplant was advertised directly to women,
not to doctors, but did not warn consumers of the potential dangers. The
Court held that Defendant cannot engage in deceptive advertising and
they had a duty to warn.
101. In MacDonald v. Ortho Pharmaceutical Corp., the Massachusetts
Supreme Court concluded that, due to the significant participation of the
patient in birth control pill decisions, the limited participation of doctors,
the ease of making direct warnings to patients, and the considerable risks
of the medication, the manufacturer had a duty to provide warnings
directly to the patients and could not simply rely on warnings made to
their doctors. MacDonald v. Ortho Pharm. Corp., 475 N.E.2d 65, 70
(Mass. 1985).
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medical marijuana.102 The medical history and physical exam focuses on
whether the patient has (or might have) a certifiable condition.103
Laboratory testing is not required and no other medications are
prescribed.104 Doctors may perform evaluations as frequently as every
fifteen minutes105 and clinics may be open six or seven days per week.106
Clinics advertise heavily on the internet and in print.107 Facilities may
even waive the evaluation fee if the doctor cannot certify the patient
for medical marijuana.108 The physicians working in medical marijuana
clinics, predominantly naturopathic physicians,109 have no special
medical training in the pharmacology or prescribing of medical
cannabis.110 Because medical cannabis is not regulated by the federal
government like a prescription drug, cannabis manufacturers are not
required to provide health care providers with continuing education,
product
information,
dosing
instructions,
warnings,
or

102. Kevin P. Hill, Medical Marijuana for the Treatment of Chronic Pain and
Other Psychiatric Problems: A Clinical Review, 313 J. AM. MED. ASS’N
2474 (2015).
103. What to Expect, CANNA-CENTERS, https://www.canna-centers.com/whatto-expect/ (last visited Sep. 22, 2018).
104. See Dianne Cochrane, Marijuana Card: Medical Marijuana OK’d After 8
Minutes, 6 Questions, BILLINGS GAZETTE (Aug. 21, 2010),
https://billingsgazette.com/news/local/medical-marijuana-card-ok-dafter-minutes-questions/article_873a0ad2-adaf-11df8799001cc4c002e0.html; Melissa Sherrard, What to Expect When You Visit a
Medical
Marijuana
Doctor,
CIVILIZED
(June
5,
2017),
https://www.civilized.life/articles/what-to-expect-when-you-visit-themedical-marijuana-doctor/.
105. See, e.g., Frequently Asked Questions, SW. MEDICAL MARIJUANA
EVALUATION CTR., http://www.evaluationtoday.com/medical_marijuana
_faqs.html (last visited Jan. 10, 2019).
106. See, e.g., ARIZ. GREEN LIFE, https://azgreenlife.com/ (last visited Jan.
10, 2019).
107. Eli McVey, Chart: Most Effective Forms of Advertising for Cannabis
Businesses,
MARIJUANA
BUS.
DAILY
(Nov.
12,
2017),
https://mjbizdaily.com/wp-content/uploads/2017/11/11-13-17COTW.png.
108. MEDICAL
MARIJUANA
TREATMENT
CLINICS
https://www.mmtcfl.com / (last visited Jan. 11, 2019).

FLA.,

109. Medical Marijuana Annual Report A.R.S. §36-2809, ARIZ. DEP’T.
HEALTH SERV. 26 (Jan. 14, 2016), https://www.azdhs.gov/documents
/licensing/medical-marijuana/reports/2015/2015-mm-annual-report160114.pdf.
110. ARIZ. DEP’T HEALTH SERV., ADHS12-017291, MEDICAL MARIJUANA
ANNUAL REPORT A.R.S. § 36-2809 (Jan. 14, 2016), available at
https://www.azdhs.gov/documents/licensing/medical-marijuana/reports
/2015/2015-mm-annual-report-160114.pdf.
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contraindications.111 Dispensaries provide limited information and most
patients are left to educate themselves.
In summary, medical marijuana is a pharma-pseudical, dispensed
in a manner that circumvents the Learned Intermediary Doctrine,
similar to birth control medication,112 because: (1) the product is heavily
marketed directly to consumers; (2) patients take a very prominent role
in the decision to use the medication; and (3) the role of the physician
is less significant in comparison to other therapeutic decisions.
Participants in the medical marijuana supply chain have a duty to
warn, which must be directed at the patient rather than the physician.

IV. Health Effects of Cannabis & Cannabinoids
A.

Beneficial Effects of Cannabinoids

Cannabis is an old remedy. Written records of cannabis use date
back to the sixth century B.C.E.113 Cannabis was introduced to Western
medicine in the mid-1800’s and was included in the Third Edition of
the United States Pharmacopeia in 1851.114 It was used as an analgesic,
anticonvulsant, and sedative-hypnotic until its sale and distribution
became illegal under federal law in 1937.115 In 1996, cannabis became
legal for medicinal purposes in California.116 Because medical marijuana
is still illegal under federal law, research into the benefits and risks of
its administration has been sharply circumscribed in the United
States.117 For example, in a letter to Congressman Tim Walz,
Department of Veterans Affairs Secretary David Shulkin wrote, “VA is
committed to researching and developing effective ways to help
Veterans cope with post-traumatic stress disorder and chronic pain
conditions . . . [h]owever, federal law restricts VA’s ability to conduct

111. See PLR Requirements for Prescribing Information, U.S. FOOD & DRUG
ADMIN.,
https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/l
awsactsandrules/ucm084159.htm (last updated Dec. 4, 2019).
112. Supra note Part VII.
113. Ethan B. Russo, History of Cannabis and its Preparations in Saga,
Science, and Sobriquet, 4 CHEMISTRY & BIODIVERSITY 1614, 1625-26
(2007).
114. NAT’L ACAD. SCIENCES, ENG’G, & MED., supra note 11, at 43.
115. Kaloyan Ivanov, High Times: The Evolution of the Stigma on Marijuana
and Attempts to Tear it Down, 13 EUKARYON 61 (2017).
116. NAT’L ACAD. OF SCI., ENG’G, & MED., supra note 11, at 67-68.
117. Sarah See Stith & Jacob Miguel Virgil, Federal Barriers to Cannabis
Research, 332 SCIENCE 1182, 1182 (2016).
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research involving medical marijuana, or to refer veterans to such
projects.”118
Cannabis appears to be an effective treatment for the reduction of
chronic pain, especially neuropathic pain.119 In a review of five “highquality randomized controlled clinical trials,” each demonstrated the
analgesic effects of smoked cannabis.120 In a meta-analysis of twentyeight placebo-controlled studies using predominantly plant-derived
cannabinoids, Whiting found that the odds of improvement in pain
control in the cannabis group increased by thirty percent, and the effect
was dose-dependent.121 Chronic pain was mostly neuropathic but other
etiologies were included.122 A study of 244 chronic pain patients
determined that medical cannabis use was associated with a sixty-four
percent reduction in opioid use, fewer side effects, and a forty-five
percent improved quality of life.123
The efficacy of cannabis as a treatment for cancer is speculative as
there is insufficient primary research to suggest a therapeutic benefit.124
However, there is conclusive evidence that cancer chemotherapyinduced nausea and vomiting can effectively be treated by oral
cannabinoids as antiemetics.125 Cannabinoids with high THCconcentrations were comparable to standard antiemetics in efficacy, but
combinations of the two drugs were non-synergistic.126 High CBD
preparations have not been tested for treatment of chemotherapyinduced emesis.127
Anorexia and weight loss contribute to the morbidity and mortality
of numerous diseases and cannabis is moderately beneficial in averting

118. Katie Zezima, VA Says it Won’t Study Medical Marijuana’s Effect on
Veterans, WASH. POST (Jan. 16, 2018), https://www.washingtonpost.com
/news/post-nation/wp/2018/01/16/va-says-it-wont-study-medicalmarijuanas-effect-on- veterans/.
119. Seddon R. Savage et al., Cannabis in Pain Treatment: Clinical &
Research Considerations. 17 J. PAIN 654, 662 (2016).
120. Id. at 657.
121. Penny Whiting et al., Cannabinoids for Medical Use: A Systematic
Review and Metanalysis, 313 J. AM. MED. ASS’N 2456, 2460 (2018).
122. The other conditions included cancer pain, multiple sclerosis, rheumatoid
arthritis, musculoskeletal issues, and chemotherapy-induced pain. Id.
123. Kevin F. Boehnke et al., Medical Cannabis Use is Associated with
Decreased Opiate Medication Use in a Retrospective Cross- Sectional
Survey of Patients with Chronic Pain, 17 J. PAIN 739, 741 (2016).
124. NAT’L ACAD. SCIENCES, ENG’G, & MED., supra note 11, at 91.
125. Whiting et al., supra note 121, at 2459.
126. Id. at 2469.
127. See id.

243

Health Matrix·Volume 29·Issue 1·2019
High Times Ahead: Products Liability in Medical Marijuana

those effects.128 Two out of three studies showed some improvement in
appetite in cancer patients.129 In women with anorexia nervosa, low dose
THC was associated with weight gain despite no change in the
psychopathology of the eating disorder itself.130
An Israeli group reported on the treatment of seventy-four children
and adolescents with cannabis for intractable epilepsy.131 Although
ethical considerations precluded the use of a control group, the results
were dramatic. Eighteen percent of the subjects experienced a 75-100%
reduction in seizures; thirty-four percent had a fifty to seventy-five
percent reduction in seizures; twelve percent had a twenty-five to fifty
percent reduction in seizures; and twenty-six percent had less than a
twenty-five percent reduction in seizures.132
Medical marijuana has been advocated for treatment of spasticity
associated with multiple sclerosis and spinal cord injury.133 Multiple
reviews have concluded that oral cannabis is probably effective for
reducing spasticity in multiple sclerosis, but there was insufficient
evidence to support its efficacy in spinal cord injuries.134 In patients
with tics from Tourette’s syndrome, oral THC was effective in reducing
tic frequency.135 However, cannabis was of no benefit for Amyotrophic
Lateral Sclerosis (ALS) or for the choreiform movements of
Huntington’s Disease.136
CBD capsules were found to improve the quality of life in a twentyone-patient randomized, double-blind, placebo-controlled study of

128. Jeffrey E. Beal et al., Dronabinol as a Treatment for Anorexia Associated
with Weight Loss in Patients with AIDS, 10 J. PAIN SYMPTOM MGMT. 89,
89 (1995).
129. ESLEY A. SMITH ET AL., CANNABINOIDS FOR NAUSEA AND VOMITING
ADULTS WITH CANCER RECEIVING CHEMOTHERAPY 14 (2015).

IN

130. Alin Andries et al., Dronabinol in Severe, Enduring Anorexia Nervosa: A
Randomized Controlled Trial, 47 INT. J. EATING DISORDERS 18, 22 (2014).
131. Intractable epilepsy is a seizure disorder in which a patient’s seizures are
not controlled with treatment. These seizures are also referred to as
“refractory.” Michal Tzadok et al, CBD-Enriched Medical Cannabis for
Intractable Pediatric Epilepsy: The Current Israeli Experience, 35
SEIZURE: EUROPEAN JOURNAL OF EPILEPSY 41, 41 (2016).
132. Id.
133. NAT’L ACAD. SCIENCES, ENG’G, & MED, supra note 11, at 2463.
134. Id. at 103.
135. K.R. Müller-Vahl et al., Influence of Treatment of Tourette Syndrome
with D9-Tetrahydrocannabinol (D9-THC) on Neuropsychological
Performance, 34 PHARMACOPSYCHIATRY 19, 19 (2001).
136. NAT’L ACAD. SCIENCES, ENG’G, & MED, supra note 11, at 106.
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Parkinson’s disease.137 Smoked cannabis also showed a statistically
significant improvement in Parkinsonian rigidity, tremor, and
bradykinesia in a similar study.138 No therapeutic effect from cannabis
was evident in dementia.139
Although cannabis lowers intraocular pressure for two hours,140 it is
ineffective for the treatment of glaucoma.141 Patients with traumatic
brain injury or intracranial hemorrhage had better outcomes with
cannabis use.142 Individuals with social anxiety disorder were benefitted
by cannabis use.143 Depression was unresponsive to cannabis; however,
cannabinoids improved short-term sleep in patients with pathological
sleep disturbances, including fibromyalgia, sleep apnea, and chronic
pain.144
Psychological disorders also vary in their responsiveness.
Randomized trials are underway to assess the potential benefits of
cannabis in post-traumatic stress disorder (PTSD).145 One study of male
Canadian soldiers with PTSD showed a considerable reduction in
nightmares and an improvement in general well-being with oral THC
treatment.146 Cannabis showed no benefit in patients with schizophrenia
or other psychoses.147
The limited research conducted with medical cannabis has
produced positive results in a variety of diagnoses; however, more
research is needed to evaluate symptom relief and monitor outcomes.

137. Marcos Hortes N. Chagas et al., Effects of Cannabidiol in the Treatment
of Patients with Parkinson’s Disease: An Exploratory Double-Blind Trial,
28 J. PSYCHOPHARAMCOLOGY 1088, 1090 (2014).
138. Itay Lotan et el., Cannabis (Medical Marijuana) Treatment for Motor
and Non-Motor Symptoms of Parkinson Disease: An Open-Label
Observational Study, 37 CLINICAL NEUROPHARMACOLOGY 41, 42 (2014).
139. S. KRISHNAN, ET AL., CANNABINOIDS FOR THE TREATMENT OF DEMENTIA 8
(2009).
140. Ileana Tomida et al., Effect of Sublingual Application of Cannabinoids on
Intraocular Pressure: A Pilot Study, 15 J. GLAUCOMA 349 (2006).
141. Whiting et al., supra note 121, at 2464.
142. NAT’L ACAD. SCIENCES, supra note 11, at 116.
143. Whiting et al., supra note 121, at 2463.
144. Id. at 2464.
145. Rakesh Jetly et al., The Efficacy of Nabilone, A Synthetic Cannabinoid,
in the Treatment of PTSD-Associated Nightmares: A Preliminary
Randomized, Double-Blind, Placebo-Controlled Cross-Over Design Study,
51 PSYCHONEUROENDOCRINOLOGY 585, 587 (2015).
146. Id.
147. See BENJAMIN C. MCLOUGHLIN
(2014).

ET AL.,
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B.

Adverse Effects of Cannabinoids

Medical cannabis has produced adverse reactions in certain disease
states and in specific groups of patients. Increased risk of acute
myocardial infarction was not found in cannabis users, but limited
evidence suggested that cannabis use could acutely trigger a myocardial
infarction or an ischemic stroke.148 Inhalation of cannabis smoke by
individuals with pre-existing angina reduces the amount of exercise
required to precipitate an angina attack by fifty percent and has been
associated with a “five-fold increase[d] risk of Myocardial
Infarctions . . . in the first hour after” smoking.149
No statistically significant association was found between smoking
cannabis and lung cancer,150 head and neck cancers,151 esophageal
cancers,152 or other cancers except for non-seminoma type testicular
cancer.153 Cannabis smoke, however, does contain many of the same
compounds as tobacco smoke.154 There is strong evidence that cannabis
smoke is not only carcinogenic, but also potentially more cytotoxic and
mutagenic than cigarette smoke.155 Cannabis smokers retain three times
the level of tar and five times the level of carbon monoxide in their
lungs compared with tobacco smokers.156 Cannabis smokers also inhale
twenty times the level of ammonia and up to five times the level of

148. NAT’L ACAD. SCIENCES, ENG’G, & MED, supra note 11, at 166.
149. Justin Lee et al., Cannabis and Myocardial Infarction: Risk Factors and
Pathogenetic Insights, 1 SCIFED J. CARDIOLOGY 1 (2017).
150. Li Rita Zhang et al., Cannabis Smoking and Lung Cancer Risk: Pooled
Analysis in the International Lung Cancer Consortium, 136 INT’L J.
CANCER 894, 896 (2015).
151. M.F.F. de Carvalho et al., Head and Neck Cancer Among Marijuana
Users: A Meta-Analysis of Matched Case-Control Studies, 60 ARCHIVES
OF ORAL BIOLOGY 1750, 1753 (2015).
152. See Mia Hashibe et al., Marijuana Use and the Risk of Lung and Upper
Aerodigestive Tract Cancers: Results of a Population-based Case-control
Study, 15 CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION 1829, 1830
(2006).
153. J. Gurney et al., Cannabis Exposure and Risk of Testicular Cancer: A
Systematic Review and Meta-Analysis, 15 BMC CANCER 1, 5 (2015),
available
at
https://bmccancer.biomedcentral.com/articles/10.1186/
s12885-015-1905-6.
154. Rebecca M. Maertens et al., The Genotoxicity of Mainstream and
Sidestream Marijuana and Tobacco Smoke Condensates, 22 CHEM. RES.
TOXICOLOGY 1406, 1406 (2009).
155. Id.
156. Tzu-Chin Wu et al., Pulmonary Hazards of Smoking Marijuana as
Compared with Tobacco, 318 NEW ENG. J. MED. 347, 350 (1988).
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hydrogen cyanide as tobacco smokers.157 Habitual smoking of cannabis
is associated with a higher incidence of wheezing, coughing, and phlegm
production as well as an increased risk of developing or exacerbating
chronic obstructive pulmonary disease.158 Cessation of cannabis smoking
or switching to a vaporizer diminished these symptoms.159
Driving impairment occurs early in occasional cannabis users and
requires a THC blood level of just 2-5 ng/ml.160 Smoking or vaporizing
ten milligrams of THC yielded blood levels at or above 5 ng/mL within
ten minutes.161 Consuming a fifteen-milligram edible produced the same
blood level in two to four hours.162 In other words, occasional cannabis
users become impaired early and often. Not surprisingly, cannabis use
is substantially linked to an increased risk of motor vehicle accidents
and a higher blood THC level correlates with an increased likelihood of
an accident.163 It takes six to eight hours for the impairment to
resolve.164 Combined use of cannabis and alcohol increases accident risk
more than either substance alone.165
Deaths related to cannabis use are extremely uncommon,166
however, among the pediatric population, cannabis exposure was
related to CNS and respiratory depression.167 Physicians in Colorado
conducted a retrospective analysis of children under age twelve who
were evaluated at the emergency room of a tertiary care children’s
hospital in Colorado.168 Prior to legalization, no pediatric cases of
157. David Moir et al., A Comparison of Mainstream and Sidestream
Marijuana and Tobacco Cigarette Smoke Produced under Two Machine
Smoking Conditions, 21 CHEM. RES. TOXICOLOGY 494, 494 (2007).
158. NAT’L ACAD. SCIENCES, ENG’G, & MED, supra note 11, at 181-88.
159. Id. at 192.
160. Rebecca L. Hartman & Marilyn A. Huestis, Cannabis Effects on Driving
Skill, 59 CLINICAL CHEMISTRY 478, 478 (2012).
161. COLO. DEP’T PUB. HEALTH & ENV’T, MONITORING HEALTH CONCERNS
RELATED TO MARIJUANA IN COLORADO: 2016 (2016), available at
http://www.colorado.gov/cdphe/marijuana-health-report.
162. Id. at 131.
163. Ole Rogeberg & Rune Elvik, The Effects of Cannabis Intoxication on
Motor Vehicle Collision Revisited and Revised, 111 ADDICTION 1348, 1348
(2016).
164. COLO. DEP’T PUB. HEALTH & ENV’T, supra note 161, at vii.
165. Combining Cannabis and Alcohol Amplifies Crash Risks, ASS’N FOR
PSYCHOL. SCI. (July 24, 2015), https://www.psychologicalscience.org
/news/motr/combining-cannabis-and-alcohol-amplifies-crash-risks.html.
166. NAT’L ACAD. SCIENCES, ENG’G, & MED, supra note 11, at 231-232.
167. Sophie Le Garrec et al., Cannabis Poisoning in Children, 40 INTENSIVE
CARE MED. 1394, 1394 (2014).
168. George Sam Wang et al., Pediatric Marijuana Exposures in a Medical
Marijuana State, 167 J. AM. MED. PEDIATRICS, 630, 630 (2013).

247

Health Matrix·Volume 29·Issue 1·2019
High Times Ahead: Products Liability in Medical Marijuana

cannabis overdose occurred; post-legalization, there were fourteen
confirmed cases within a two-year period.169 Of the eight patients
admitted to hospital, two required admission to the intensive care
unit.170 Seven of the eight exposures were from edibles,171 likely because
they often look like and taste like regular candies, soft drinks, and baked
goods.172
Compared with adults, the effects of pediatric cannabis intoxication
are more pronounced and occur at lower doses.173 Common symptoms
include ataxia, somnolence, lethargy, altered mental status, and
obtundation (reduced alertness).174 Rarely, children will present with
severe symptoms, such as apnea, cyanosis (discoloration of skin),
bradycardia (slowed heart rate), hypotonia (decreased muscle tone),
and opisthotonus (severe hyperextension and spasticity).175
The Committee on Obstetric Practice of the American College of
Obstetrics and Gynecology reviewed the effects of marijuana use during
pregnancy and lactation.176 Children exposed to marijuana in utero
achieved lower scores on visual problem solving, visual-motor
coordination, and visual analysis tasks.177 Reduced attention spans and
increased behavioral problems were evident.178 Newborns exposed to
cannabis in utero had shorter birth lengths, lower birth weights, and
smaller head circumferences, all of which correlated with the amount of
maternal marijuana use during the first and second trimesters of
pregnancy.179 This committee recommended counseling pregnant
women about the potential adverse health consequences of cannabis use

169. Id. at 631.
170. Id. at 632.
171. Id. at 630.
172. Id. at 633.
173. Laura M. Borgelt et. al., The Pharmacologic and Clinical Effects of
Medical Cannabis, 33 PHARMACOTHERAPY 195, 205 (2013).
174. Id.
175. Borgelt et al., supra note 173, at 205.
176. AM. COLL. OBSTETRICIANS & GYNECOLOGISTS, COMMITTEE OPINION NO.
722, MARIJUANA USE DURING PREGNANCY AND LACTATION (2017),
available at https://www.acog.org/Clinical-Guidance-and-Publications
/Committee-Opinions/Committee-on-Obstetric-Practice/Marijuana-UseDuring-Pregnancy-and-Lactation?IsMobileSet=false.
177. Id.
178. Id.
179. Id.
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during pregnancy.180 Because cannabinoids are found in breast milk,
they also advised lactating women to discontinue marijuana use.181
A study of 975 individuals in upstate New York to assess whether
cannabis use over an eight-year period during childhood, adolescence,
and the early twenties was predictive of neurocognitive and behavioral
problems in the late twenties.182 The study, which was controlled for
age, gender, income, and other mental disorders, clearly demonstrated
that marijuana use was predictive of later health problems.183 Cannabis
users were thirty-six percent more likely to have neurocognitive
problems, twenty-six percent more likely to have lower academic
functioning and achievement, and fifty-two percent more likely to have
general malaise.184 The researchers hypothesized that “neurocognitive
impairment may be a mechanism that mediates the association between
marijuana use and lower academic achievement and functioning.”185
The results of studies on the effects of marijuana use by adolescents
and young adults have been reported by the Colorado Retail Marijuana
Public Health Advisory Committee (Colorado Retail Committee).186
The Colorado Retail Committee found moderate evidence that
adolescents and young adults who are regular marijuana users are: (1)
more likely than non-users to have cognitive and academic ability
impairment for at least twenty-eight days after last use; (2) less likely
than non-users to graduate from high school; (3) more likely than nonusers to increase their use and become addicted to marijuana in
adulthood; and (4) more likely than non-users to use and become
addicted to alcohol or tobacco in adulthood.187 The Colorado Retail
Committee found “substantial evidence that adolescent and young
adult marijuana users are more likely than non-users” to: (1) “use and
be addicted to illicit drugs in adulthood;” and (2) develop psychotic
symptoms or disorders like schizophrenia in adulthood.188 Quitting
180. Id.
181. Id.; See also Kerry A. Bertrand et at., Marijuana Use by Breastfeeding
Mothers and Cannabinoid Concentrations in Breast Milk, 142 PEDIATRICS
1, 3-5 (2018).
182. Judith S. Brook et al., The Association Between Early Marijuana Use
and Subsequent Academic Achievement and Health Problems: A
Longitudinal Study, 17 AM. J. OF ADDICTION 155, 156-59 (2008).
183. AM. COLL. OBSTETRICIANS & GYNECOLOGISTS, supra note 176.
184. Id.
185. Whiting et al., supra note 121, at 2469.
186. Marijuana Use Among Adolescents and Young Adults, COLO. DEP’T PUB.
HEALTH & ENV’T at 95 (January 12, 2015), http://dhss.alaska.gov
/dph/Director/Documents/marijuana/Monitoring_Health_Concerns_R
elated_to_Marijuana_in_Colorado_2014.pdf.
187. Id. at 98.
188. Id.
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marijuana was associated with lower risks of cognitive and mental
health problems than for those who continued to use.189
A prospective, longitudinal study was conducted to examine the
association between persistent cannabis use and neuropsychological
functioning in more than 1,000 individuals over a twenty-year period,
starting at birth.190 Persistent cannabis use commencing in adolescence
was associated with a statistically significant decline in overall
neuropsychological functioning.191 Moreover, the cannabis users who
began persistent use in adolescence and later discontinued cannabis use
for at least one year did not see restored neuropsychological
functioning.192
Adverse effects from cannabis most frequently involve the CNS.193
The most common effects are intoxication reactions, such as dizziness,
drowsiness, and impairment of perceptual and sensory functions.194
Twenty-four percent of patients using cannabis as an antiemetic became
“high,” a state characterized by laughing, elation, and
hyperawareness.195 Up to ten percent of medical marijuana users
developed paranoia and abnormal thinking; more than ten percent
developed amnesia and hallucinations; and less than one percent
experienced depersonalization and confusion.196
A meta-analysis of 83 studies was performed, investigating the
relationship between cannabis and the age of onset of psychosis.197 The
authors found the onset of psychosis among cannabis users occurred
almost three years earlier than non-users, supporting their hypothesis
that cannabis use has a causal role in the development of psychosis in
predisposed individuals.198

189. Id.; See generally Ciera Parish, Rules Are Meant to Be Broken: The Organ
Procurement and Transplantation Network Should Allow Pediatric
Transplantation of Adult Lungs, 28 J.L. & HEALTH 319, 323-324 (2015).
190. Madeline H. Meier et al., Persistent Cannabis Users Show
Neuropsychological Decline from Childhood to Midlife, 109 PROCEEDINGS
OF THE NAT’L ACAD. OF SCI. OF THE U.S. 1, 1 (2012).
191. Id. at 6.
192. Id. at 5.
193. HEALTH CAN., INFORMATION FOR HEALTHCARE PROFESSIONALS: CANNABIS
(MARIHUANA, MARIJUANA) AND THE CANNABINOIDS 87 (2018), available at
http://www.veterans.gc.ca/pdf/services/health/cannabis-medicalpurposes/information-for-health-professionals.pdf.
194. Id.
195. Id.
196. Id.
197. Matthew Large et al., Cannabis Use and Earlier Onset of Psychosis: A
Systematic Meta-Analysis, 68 ARCHIVES OF GEN. PSYCHIATRY 555 (2011).
198. Id.
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THC use has been correlated with episodes of acute psychosis. In a
randomized, controlled trial, intravenous doses of THC equivalent to
typical cannabis cigarette usage (1.0 to 3.5% THC) produced acute
cognitive and behavioral effects, including paranoid and grandiose
delusions, hallucinations, depersonalization, distorted sensory
perceptions, altered bodily perceptions, feelings of unreality, and
extreme slowing of time.199 Subjects manifested a flat affect, reduced
rapport, absence of spontaneity, psychomotor retardation, and
emotional withdrawal.200
Cannabis use increased the risk of adverse psychiatric effects for
individuals with frank schizophrenia or with a family history of the
disorder.201 Cannabis users developed schizophrenia an average of 1.5
years earlier than non-users.202 In a study of 1,000 children followed
from birth to age twenty-six, cannabis use was associated with a threefold risk of the development of psychotic disorders.203 The authors
suggested that “psychologically vulnerable adolescents” should be
strongly discouraged from using cannabis.204
THC causes acute and transient episodes of anxiety, similar to
panic attacks, in naïve cannabis users.205 In a study of French highschool students, cannabis users reported significantly higher rates of
depression and suicidal behaviors.206 Cannabis is one of the most
frequently abused drugs in bipolar individuals, and there is a strong
association between cannabis use and manic/hypomanic episodes or
symptoms.207 Cannabis use also reduced the age of onset of bipolar
disease by an average of nine years.208
Frequent cannabis use may also lead to additional problems. Adults
who smoked cannabis regularly as adolescents manifest impaired neural
connectivity in the precuneus of the superior parietal lobe and the
hippocampal fimbria,209 which control integration functions (alertness

199. DC D’Souza et al., The Psychotomimetic Effects of Intravenous delta-9tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis,
29 NEUROPSYCHOPHARMACOLOGY 1558 (2004).
200. Id. at 1563.
201. HEALTH CAN., supra note 193, at 92.
202. Id.
203. Id.
204. Id.
205. Id. at 90.
206. Henri Chabrol et al., Cannabis Use and Suicidal Behaviours in HighSchool Students, 33 ADDICTIVE BEHAVIOR 152, 154 (2008).
207. HEALTH CAN., supra note 193, at 90.
208. Id. at 91.
209. Id
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and awareness) and learning and memory, respectively.210 Reduced
connectivity has also been reported in executive functioning areas of
the prefrontal cortex.211 Approximately nine percent of individuals who
experiment with marijuana become addicted according to the DSM-IV
criteria.212 The addiction rate increases to seventeen percent in teenage
smokers and twenty-five to fifty percent in daily smokers.213
The safety of cannabis use (12.5% THC) in chronic non-cancer pain
was examined in a prospective cohort study.214 Non-serious adverse
events occurred 818 times in the cannabis group compared with only
581 events in non-users.215 Compared with controls, the rates of nervous
system disorders, respiratory disorders, infectious disorders, and
psychiatric disorders were significantly higher in the cannabis group.216
In a similar study, the rate of non-serious adverse events was eighty-six
percent higher in participants using medical cannabinoids versus
controls.217 The incidence of serious adverse events was not higher in
the cannabis group.218
Foods and beverages infused with cannabis have added risks,
including a greater risk of poisoning.219 Unlike smoked marijuana,
edibles require two hours or more to reach their peak effect, subject to
food intake and concomitant use of alcohol or other medications.220 This

210. Id.
211. Nora D. Volkow et al., Adverse Health Effects of Marijuana Use, 370 NEW
ENG. J. MED. 2219 (2014).
212. Id.
213. NIH - NAT’L INST. DRUG ABUSE, MARIJUANA FACTS FOR TEENS 3 (2013),
available
at
https://www.drugabuse.gov/sites/default/files/teens_
brochure_2013.pdf.
214. Mark A. Ware et al., Cannabis for the Management of Pain: Assessment
of Safety Study (COMPASS), 16 J. PAIN 1233, 1234 (2015).
215. Id. at 1237.
216. Id.
217. Tongtong Wang et al., Adverse Effects of Medical Cannabinoids: A
Systematic Review, 178 CAN. MED. ASS’N J. 1669, 1676 (2008).
218. Id. at 1669.
219. See Ont. Pub. Health Ass’n, Position Paper on The Public Health
Implications of the Legalization of Recreational Cannabis (2017) at 17,
available at http://www.opha.on.ca/getmedia/6b05a6bc-bac2-4c92-af1862b91a003b1b/The-Public-Health-Implications-ofthe-Legalization-ofRecreational-Cannabis.pdf.aspx?ext=.pdf.
220. Mary Barna Bridgeman et al., Medicinal Cannabis: History,
Pharmacology, And Implications for the Acute Care Setting, 42
PHARMACY & THERAPEUTICS 180, 182 (Mar. 2017).
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delayed effect leads some individuals to use excess amounts, which can
lead to symptoms of overdose and poisoning.221
Drug interactions are common, especially when cannabis is used in
conjunction with other CNS depressants, such as sedative-hypnotics or
alcohol.222 THC is oxidized via the hepatic cytochrome P450 pathway;
therefore, drugs that inhibit the P450 pathway may increase the
bioavailability of THC and cause overdosing.223 Examples of these drugs
include selective serotonin reuptake inhibitors (Prozac, Luvox), proton
pump inhibitors (Prilosec, Tagamet), antibiotics (Biaxin, Emycin),
anti-fungals (Nizoral, Diflucan), and calcium antagonists (Calan,
Cardizem).224
Health Canada has promulgated a list of nine precautions that their
physicians should consider before recommending medical cannabis:


Cannabis should not be used in any person under the age of 18,
or in any patient who has a history of hypersensitivity to any
cannabinoid or to smoke. The adverse effects of cannabis use
on mental health are greater during development, particularly
during adolescence, than in adulthood . . .



Cannabis should not be used in patients with severe cardiopulmonary disease because of occasional hypotension, possible
hypertension, syncope, or tachycardia . . .



Smoked cannabis is not recommended in patients with
respiratory insufficiency such as asthma or chronic obstructive
pulmonary disease . . .



Cannabis should not be used in patients with severe liver or
renal disease. Patients with ongoing chronic hepatitis C should
be strongly advised to abstain from daily cannabis use, as this
has been shown to be a predictor of steatosis severity in these
individuals . . .

221. Marijuana: How Can It Affect your Health, CENTERS FOR DISEASE
CONTROL & PREVENTION (Jan. 27, 2017), https://www.cdc.gov/
marijuana/health-effects.html.
222. HEALTH CAN., supra note 193, at 15.
223. Adrian Devit-Lee, CBD-Drug Interactions: Role of Cytochrome P450,
PROJECT CBD (Sep. 8, 2015) https://www.projectcbd.org/science/
cannabis-pharmacology/cbd-drug-interactions-role-cytochrome-p450; See
Drugs that May Interact with CBD Oil, CBD OIL REV.
https://cbdoilreview.org/cbd-cannabidiol/cbd-p-450-enzyme/
(last
visited Sep. 29, 2018).
224. HEALTH CAN., supra note 193, at 80.
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Cannabis should not be used in patients with a personal history
of psychiatric disorders (especially schizophrenia), or a familial
history of schizophrenia . . .



Cannabis should be used with caution in patients with a history
of substance abuse, including alcohol abuse, because such
individuals may be more prone to abuse cannabis, which itself,
is a frequently abused substance . . .



Patients with mania or depression and using cannabis or a
cannabinoid should be under careful psychiatric monitoring . . .



Cannabis should be used with caution in patients receiving
concomitant therapy with sedative-hypnotics or other
psychoactive drugs because of the potential for additive or
synergistic CNS depressant or psychoactive effects. Cannabis
may also exacerbate the CNS depressant effects of alcohol and
increase the incidence of adverse effects. Patients should be
advised of the negative effects of cannabis/cannabinoids on
memory and to report any mental or behavioral changes that
occur after using cannabis . . .



Cannabis is not recommended for women who are pregnant,
breastfeeding, planning to become pregnant, or not using a
reliable method of contraception.225

Like most medications, cannabis has salutary effects and side
effects.226 With the paucity of research performed in the United States,
it is not possible to determine whether cannabis will ultimately be
viewed as a blessing or a curse. Nonetheless, some individual or entity
will be responsible for alerting patients to possible side effects. While
the Learned Intermediary Doctrine puts the onus on doctors to warn
patients about ethical pharmaceuticals, medical cannabis will be the
exception. Medical cannabis is heavily marketed directly to patients by
producers, and doctors only play a peripheral role as “recommenders”
and not “prescribers.” Cannabis retailers are well advised to train their
employees to discuss the use and misuse of cannabis as a way to limit
liability.

225. Id. at 79.
226. Kevin Loria, 23 Science-Backed Health benefits of Marijuana, BUS.
INSIDER (Mar. 8, 2018, 15:46) https://www.iflscience.com/health-andmedicine/23-sciencebacked-health-benefits-of-marijuana/all/.
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V. Manufacturing Defects
A.

General Considerations

When a product differs from the manufacturer’s design standards
or intended result, or if it differs from supposedly identical products
from the same manufacturer, the product has a manufacturing defect,
to wit, the design has been executed in a defective manner.227 Moreover,
the defective product must be “dangerous” and “unfit for its intended
or foreseeable uses.”228 A claim of defective manufacture “involves a
deviation from the product’s design specifications, to the injury or
potential injury of a user.”229 Manufacturing claims can be brought in
negligence, breach of warranty (implied and express), and strict
liability.230
A negligence claim has three elements: (1) a legal duty to use
reasonable care; (2) a breach of that duty; and (3) the breach was the
“proximate or legal cause” of the injury.231 Under the theory of strict
liability in tort, a plaintiff has the burden of proving that: (1) he or she
sustained an injury from the product; (2) the injury occurred because
the product was defective; and (3) the defect existed when the product
left the manufacturer’s control.232
In a number of states, the Implied Warranty of Merchantability
(U.C.C. § 2-314) has been codified in state law.233 In Arizona, A.R.S.
§ 47-2314 is identical to U.C.C. § 2-314, which reads:
B. Goods to be merchantable must be at least such as:
1. Pass without objection in the trade under the contract
description; and
2. In the case of fungible goods, are of fair average quality within
the description; and

227. See Fisher v. Pelstring, 817 F. Supp. 2d 791, 836 (D.S.C. 2012).
228. Gerber v. Hoffmann-La Roche Inc., 392 F. Supp. 2d 907, 922 (S.D. Tex.
2005) (quoting Dico v. Cisneros, 953 S.W.2d 776, 783).
229. Wankier v. Crown Equip. Corp., 353 F.3d 862, 867 (10th Cir. 2003).
230. Products Liability, JUSTIA, https://www.justia.com/products-liability/
(last visited Sep. 29, 2018).
231. U.S. Liability Ins. Co. v. Haidinger-Hayes, Inc., 1 Cal. 3d 586, 594 (Cal.
1970).
232. Fender v. Medtronic, Inc., 887 F. Supp. 1326, 1333 (E.D. Cal. 1995).
233. What Is the Warranty of Merchantability?, FINDLAW, https://
consumer.findlaw.com/consumer-transactions/what-is-the-warranty-ofmerchantability.html (last accessed Sep. 29, 2018); Edward M. Kimmel,
Used Goods and Merchantability, 13 TULSA L.J. 627, 628 (2013).
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3. Are fit for the ordinary purposes for which goods of that type
are used; and
4. Run, within the variations permitted by the agreement, of even
kind, quality and quantity within each unit and among all units
involved; and
5. Are adequately contained, packaged, and labeled as the
agreement may require; and
6. Conform to any promises or affirmations of fact made on the
container or label if any.234

The implied warranty of merchantability, which operates as a
matter of law, “does not impose a general requirement that goods
precisely fulfill the expectations of the buyer.”235 Under the U.C.C., the
Implied Warranty of Fitness for Particular Purpose states:
Where the seller at the time of contracting has reason to know
any particular purpose for which the goods are required and that
the buyer is relying on the seller’s skill or judgment to select or
furnish suitable goods, there is unless excluded or modified under
the next section an implied warranty that the goods shall be fit
for such purpose.236

This warranty is not limited to merchants and does not require any
showing that the product was defective.
U.C.C. § 2-313 sets out the elements of an express warranty:
(1) Express warranties by the seller are created as follows:
(a) Any affirmation of fact or promise made by the seller to the
buyer which relates to the goods and becomes part of the basis of
the bargain creates an express warranty that the goods shall
conform to the affirmation or promise.
(b) Any description of the goods which is made part of the basis
of the bargain creates an express warranty that the goods shall
conform to the description.
(c) Any sample or model which is made part of the basis of the
bargain creates an express warranty that the whole of the goods
shall conform to the sample or model.
234. Ariz. Rev. Stat. Ann. § 47-2314 (2018); U.C.C. § 2-314 (AM. L. INST. &
UNIF. L. COMM’N 2002).
235. Skelton v. General Motors Corp., 500 F. Supp. 1181, 1191 (N.D. Ill. 1980)
(rev’d on other grounds, 660 F2d 311 (7th Cir. 1981)).
236. U.C.C. § 2-314 (AM. L. INST. & UNIF. L. COMM’N 2002).
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(2) It is not necessary to the creation of an express warranty that
the seller use formal words such as “warrant” or “guarantee” or
that he have a specific intention to make a warranty, but an
affirmation merely of the value of the goods or a statement
purporting to be merely the seller’s opinion or commendation of
the goods does not create a warranty.237

Under various codes, statutes, and the common law, medical
marijuana product liability claims can be prosecuted for manufacturing
defects when the edible product differs from its intended result and the
product is more dangerous or unfit for its intended purpose under the
theories of negligence, strict liability, and implied warranty.
B.

Medical Marijuana Manufacturing Defect Claims
1. Pesticides

The presence of a harmful pesticide in unprocessed cannabis is most
likely a manufacturing defect, which may result in contamination of the
final product with toxic chemicals or inaccurate concentrations of THC
and other active components. When a product contains banned
pesticides or unacceptable levels of permissible pesticides, it has
deviated from the manufacturer’s specifications. Pesticides, by their
very nature, have the potential to cause physical injury to humans.238
If an injury occurs from an improper pesticide in cannabis,
manufacturing defect claims may be made under the theories of
negligence, strict liability in tort, and warranty.
The Environment Protection Agency (EPA) sets strict standards
for permissible levels of pesticides in commodities sold in the United
States, typically in the range of 10 to 10,000 parts per billion.239
Unfortunately, the EPA has refused to regulate pesticides in cannabis
plants, citing marijuana as an illegal drug under federal law.240
Consequently, pesticide regulation in marijuana cultivation can be
controlled by the states.241 While the EPA has not established standards
237. Id.
238. Christos A. Damalas & Illias G. Eleftherohorinos, Pesticide Exposure,
Safety Issues, and Risk Assessment Indicators, 8 INT’L J. ENVT’L RES. &
PUB. HEALTH 1402, 1403 (2011).
239. RODGER VOELKER & MOWGLI HOLMES, PESTICIDE USE ON CANNABIS,
CANNABIS SAFETY INST. 1, 7-9 (June 2015), available at
http://cannabissafetyinstitute.org/wp-content/uploads/2015/06/CSIPesticides-White-Paper.pdf.
240. Jack Kaskey, Pot Laced with Pesticides Forces States to Act as EPA
Stays Away, BLOOMBERG (Aug. 7, 2017), https://www.bloomberg.com
/news/articles/2017-08-02/pot-laced-with-pesticides-forces-states-to-actas-epa-stays-away.
241. Jay Feldman, Pesticide Use in Marijuana Production: Safety Issues and
Sustainable Options, 34 BEYOND PESTICIDES 14, 14 (2015).
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for cannabis,242 it is reasonable to extrapolate that the permissible
pesticide level would be comparable to other regulated commodities.
Thus, states have used EPA regulations as guidelines for cannabis.243
In Oregon, cannabis samples contained pesticide concentrations in
excess of 10,000 parts per billion in twelve percent of the cases and in
excess of 100,000 parts per million in 1.9% of the samples.244 Moreover,
cannabis extracts frequently have THC concentrations five to ten times
higher than cannabis flower.245 “THC might concentrate at five to seven
times what’s in the original plant material, but pesticides might
concentrate up to 100 times their original level.”246 As manufacturers
work to get higher THC levels for the final product, pesticide levels are
concentrating at a much higher rate. These pesticide levels grossly
exceed acceptable tolerances for any commodity sold to the public for
human consumption.247
The study of cannabis from Oregon shows a widespread pesticide
problem. For example, 389 samples of cannabis flower and 154 samples
of cannabis extract (concentrate) were tested for sixty-five pesticides.248
Of the samples tested, seven percent of flower and twenty-four percent
of concentrate samples exceeded Oregon’s statutory pesticide
tolerances.249 Some concentrates were found to contain the pesticides
carbaryl, myclobutanil, and chlorfenapyr at levels greater than 100,000
parts per billion, grossly exceeding acceptable levels for these pesticides
in any commodity.250 Moreover, chlorfenapyr is not permitted in any
food commodities.251
In 2015, Oregon Live reported the results of its own testing in “A
Tainted High.”252 They found that cannabis extract sold to medical
marijuana patients had unacceptable levels of pesticide even though the
242. Id.
243. Id. at 17, 19.
244. VOELKER & HOLMES, supra note 239, at 10.
245. Id. at 11.
246. Madison Margolin, Cannabis Concentrates Have a Problem with
Pesticides, LA WEEKLY (Feb. 27, 2017, 8:12 AM), https://www.
laweekly.com/news/la-weekly-tagged-along-for-emerald-cup-cannabisjudging-10118373.
247. VOELKER & HOLMES, supra note 239, at 11. One hundred parts per billion
is the recommended rate for products made for human consumption. Id.
at 15.
248. Id. at 7.
249. Id. at 8.
250. Id. at 11.
251. Id.
252. Noelle Crombie, A Tainted High, OR. LIVE (June 11,
http://www.oregonlive.com/marijuana-legalization/pesticides/.
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products passed mandated state testing.253 Of the ten concentrates
tested by independent labs, eight tested positive for excessive pesticide
levels.254 Of the fourteen pesticides found in those eight samples, six
were classified by the federal government as possibly or probably
carcinogenic.255 The Oregonian article suggested that laboratory
certified products sold at dispensaries are likely to contain inconsistent
and unacceptable levels of pesticide concentrations or banned
pesticides.256
The Oregonian determined that Mad Farmaceuticals’ OG Propane
Hash Oil extract contained the active ingredient in Raid insecticide as
well as three pesticides not approved for use in Oregon.257 Seven
pesticides were found in Dab Society Dutch Treat extract, including
bifenthrin, one of the pesticides on the EPA’s list of carcinogens.258 The
concentration was so high (0.5 to 0.8 parts per million), that one
toxicologist suggested that the plants used to make Dutch Treat must
have been “soaked” in bifenthrin prior to harvesting.259
A case involving the misuse of pesticides in marijuana cultivation
was filed in Denver, Colorado on October 5, 2015.260 Brandan Flores
and others filed suit against LivWell, Inc., a cannabis grower and
operator of at least fourteen retail marijuana dispensaries in Colorado.261
During the first quarter of 2015, LivWell employed a chemical
“cocktail” including the fungicide, Eagle 20, to rid the cannabis plants
of fungus, mites, worms, and other natural agents.262 Eagle 20 was not
on the list of approved pesticides in Colorado at that time.263 When
burned during the process of smoking marijuana, Eagle 20 releases

253. Id.
254. Id.
255. Id.
256. Id.
257. Id.
258. Id.
259. VOELKER & HOLMES, supra note 239, at 11.
260. Flores v. LivWell, Inc., No. 2015CV33528 (2d Dist. Colo. filed Oct. 05,
2015).
261. Matt Lamers, Leading US Marijuana Retailer LivWell Takes ‘Significant’
Ownership Stake in Canadian Producer, MARIJUANA BUS. DAILY (Nov. 8,
2017),
https://mjbizdaily.com/leading-us-marijuana-retailer-livwelltakes-significant-ownership-stake-canadian-producer/.
262. David Kelly, A First for the Marijuana Industry: A Product Liability
Lawsuit, L.A. TIMES (Oct. 8, 2015, 4:00 AM), http://www.latimes.com
/nation/la-na-marijuana-lawsuit-20151008-story.html#.
263. Id.
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hydrogen cyanide gas, a potent and well-known poison, directly into
the lungs of the smoker.264
After being alerted to the use of Eagle 20, the Denver Department
of Environmental Health placed a hold on 60,000 marijuana plants
pending an assay of the residue.265 The hold was removed after the
Department found acceptable levels of pesticide for vegetation,
although the range would have been too high for tobacco.266 Individuals
who unknowingly smoked Eagle 20-contaminated cannabis filed a class
action lawsuit, alleging breach of contract, breach of implied covenant
of good faith and fair dealing, breach of express warranty, breach of
implied warranty for a particular purpose, breach of implied warrant of
merchantability, intentional misrepresentation and concealment of
material facts, unjust enrichment, and civil conspiracy.267 Plaintiffs did
not assert bodily injury, only that they overpaid for a product with a
manufacturing defect.268
In response, Defendant LivWell filed a motion to dismiss, which
was granted on February 11, 2016.269 The court held that the plaintiffs
lacked standing because they did not suffer any physical, emotional, or
economic injuries.
Dismissal of the case against LivWell was anticipated for lack of
damages. However, had the plaintiffs been able to show a cognizable
injury-in-fact, the case would likely have been heard by a jury. As a
consequence of this case, Eagle 20 was banned, and marijuana
manufacturers and distributors recalled forty different contaminated
cannabis products during 2016.270

264. Hydrogen cyanide was the active ingredient in Zyklon B, exterminating
agent used Nazi death camps during World War II. The “Final Solution”,
ENCYCLOPEDIA,
HOLOCAUST
https://encyclopedia.ushmm.org/content/en/article/the-final-solution
(last visited Sep. 30, 2018).
265. Debra Borchardt, Marijuana Grower Sued for Using Pesticides, FORBES
(Oct.
14,
2015,
7:00
AM),
https://www.forbes.com/sites/
debraborchardt/2015/10/14/marijuana-grower-sued-for-usingpesticides/#2cea99194fd3.
266. Id.
267. Flores v. LivWell, Inc., No. 2015CV33528 (2d Dist. Colo. filed Oct. 05,
2015).
268. Id.
269. Id.
270. See Colo. Exec. Order No. D 2015-015 (Nov. 12, 2015),
https://www.colorado.gov/governor/sites/default/files/executive_orders
/2015_d_015.pdf; Ashley Simpson et al., Recent Developments in Toxic
Tort and Environmental Law, 52 TORT & INS. L.J. 683, 690 (2017).
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2. Heavy Metals and Fungus

At least one author has reported that medical marijuana is often
laced with heavy metals and fungus, which are derived from the soil in
which the marijuana grows.271 Concentrating the THC (which many
manufacturers aim to do) can lead to increased amounts of heavy
metals in the end product.272 Some manufacturers also employ butane,
another toxic chemical, to strip the plant of many other compounds to
maximize the percent of THC and profitability.273
One such fatality related to medical marijuana contamination likely
occurred in early 2017.274 According to CBS News, a young California
man undergoing intensive cancer chemotherapy and stem cell therapy
succumbed to a rare systemic fungal infection.275 He smoked medical
cannabis for the relief of chemotherapy-induced nausea and vomiting.276
After his death, twenty samples of medical marijuana taken from across
the state were predominantly contaminated with the same rare fungus
that caused his demise.277 Contaminated cannabis is the suspected cause
of at least one other life-threatening fungal infection in a nonimmunocompromised cannabis smoker.278
3. Inaccurate Medical Marijuana Testing

Testing for THC concentration in cannabis, particularly edibles, is
notoriously inaccurate.279 When products with a high THC
concentration are incorrectly labeled with a lower THC concentration,
this manufacturing defect may be responsible for the untoward effects
of excess THC consumption. Multiple parties along the chain of product
271. Brian Handwerk, Modern Marijuana is Often Laced with Heavy Metals
(Mar.
23,
2015),
and
Fungus,
SMITHSONIAN
http://www.smithsonianmag.com/science-nature/modern-marijuanamore-potent-often-laced-heavy-metals-and- fungus-180954696/?no-ist.
272. Id.
273. Id.
274. Contaminated Medical Marijuana Believed to Have Killed Cancer Patient,
CBS NEWS (Feb. 7, 2017, 11:08 AM), https://www.cbsnews.com
/news/contaminated-medical-marijuana-pot-believed-to-have-killedcancer-patient/.
275. Id.
276. Id.
277. Id.
278. Bryan B. Shapiro et al., Cryptococcal Meningitis in a Daily Cannabis
Smoker Without Evidence of immunodeficiency, BMJ CASE REPORTS
(2018), https://casereports.bmj.com/content/2018/bcr-2017-221435.full.
279. Steve P. Calandrillo & Katelyn J. Fulton, “High” Standards: The Wave
of Marijuana Legalization Sweeping America Conveniently Ignores the
Hidden Risks, Paper No. 2018-07 (U. Wash. Sch. L. Res. 2018),
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3163729.
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distribution may be liable for the injury. Moreover, failure to properly
test THC concentrations violates state law and is negligence per se.280
In 2014, the Oregon Live opened another investigation by testing
the THC concentration of fifteen cannabis-infused edibles and
comparing it to the labeled concentration.281 Only one of fifteen samples
was accurately labeled.282 Two products underestimated the THC
concentration.283 For example, cannabis ice cream had fifty-four percent
more TCH than the stated amount.284 Twelve products overstated the
THC concentration.285 Chocolate chip cookies were found to have fiftytwo milligrams of THC instead of the indicated 197 milligrams.286 Como
Treats pizza was labeled as having 350 milligrams of THC but
contained only fifty-two milligrams – an eighty-five percent
difference.287 The Oregonian also pointed out that product labels were
“inconsistent and confusing” and “[o]nly four [edibles] had expiration
dates.”288
The accuracy of cannabis labeling was reported on in the Journal
of the American Medical Association.289 Seventy-five marijuana edibles
- baked goods, beverages, and candy - were purchased in random
dispensaries located in San Francisco, Los Angeles, and Seattle.290 Two
samples of each product were assayed for THC and CBD levels using
state of the art, high-performance liquid chromatography.291 Accurate
labeling was defined as within +/- 10% of labeled values, consistent
with typical United States Pharmacopeia requirements that drugs meet

280. Alison Malsbury, Inaccurate MJ Testing Will Lead to Lawsuits, CANNA
L. BLOG, (Mar. 27, 2015), https://www.cannalawblog.com/inaccuratemarijuana-testing-will-lead-to-lawsuits/.
281. Noelle Crombie, How Potent Are Marijuana Edibles? Lab Tests Yield
Surprising
Results, OR. LIVE (June 4, 2015, 2:17 PM)
https://www.oregonlive.com/marijuana/index.ssf/2015/03/how_potent
_are_marijuana_edibl.html.
282. Id.
283. Id.
284. Id.
285. Id.
286. Id.
287. Id.
288. Id.
289. Ryan Vandrey et al., Cannabinoid Dose and Label Accuracy in Edible
Medical Cannabis Products, 313 J. AM. MED. ASS’N 2491 (2015).
290. Id.
291. Id.
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a 90-110% potency specification.292 Of the thirteen products labeled for
CBD, none were accurately labeled; nine were over-labeled and four
were under-labeled.293 With respect to THC content, only seventeen
percent of the edibles were accurately labeled, sixty percent were overlabeled, and twenty-three percent were under-labeled.294 Thus, eightythree percent of the samples were inaccurately labeled for THC
concentration. Insufficient THC concentration is unlikely to produce
the desired medical benefits. Excessive THC places patients at risk for
adverse effects.295
When medical marijuana is labeled with the incorrect THC
concentration, there is a viable claim for breach of an express warranty.
The THC concentration is a description of the goods and forms part of
the basis of the bargain. If the producer or retailer was aware, or should
have been aware, that the product was mislabeled and likely to cause
harm, fraud may be added to the claim. If testing has not been
performed or performed in an inadequate manner, the plaintiff may
have a prima facie claim for negligent misrepresentation.
Medical marijuana marked with the incorrect THC concentration
is not considered of average quality, would not pass without objection
in the trade, and is not fit for the ordinary purposes for which it is used.
Therefore, mislabeled cannabis breaches the implied warranty of
merchantability.
Consumers of medical marijuana probably lack the ability to
differentiate between dozens of strains with various chemical
compositions. In the current paradigm for obtaining medical marijuana,
the retailer often possesses the most knowledge about the products and
their effects. This places the retailer in the best position to assist the
consumer in selecting a cannabis strain or an edible that is suitable for
treating a specific symptom or debilitating condition. This is especially
true in certain diseases, like epilepsy. One study reported a reduction
in seizures of fifty percent or more in 272 patients with the use of
artisanal forms of cannabis very high in CBD.296 Strains low in CBD
were significantly less efficacious.297
292. Allen V. Loyd et al., Strength and Stability Testing for Compounded
Preparations, U.S. PHARMACOPEIA, https://www.usp.org/sites/default/
files/usp/document/FAQs/strength-stability-testing-compoundedpreparations.pdf (last visited Sept. 28, 2018).
293. Vandrey et al., supra note 289, at 2491.
294. Id.
295. Id.
296. See Dustin Sulak et al., The Current Status of Artisanal Cannabis for the
Treatment of Epilepsy in the United States, 70 EPILEPSY BEHAVIOR 328
(2017).
297. Kerstin Iffland & Franjo Grotenhermen, An Update on Safety and Side
Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal
Studies, 2 CANNABIS & CANNABIDIOL RES. 139, 152 (2017).
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If the customer asks the seller to recommend a cannabis strain or
an edible to treat seizures, the customer is relying on the seller’s skill
and judgment to select the proper product. The seller must understand
that only a product with a very high CBD concentration will be
efficacious. If the seller recommends a product without the requisite
concentration of CBD because the medical marijuana has been
incorrectly assayed and labeled or because the seller is unaware of the
association between CBD concentration and seizure abatement, the
seller has breached the warranty of fitness for a particular purpose.
Manufacturing defect claims will be prolific without significant
reforms in the cannabis industry. Plants need to be cultivated without
noxious pesticides, heavy metals, or fungi. Concentrations of THC and
CBD need to be accurate assayed and labeled. Retailers should know
which cannabis strain is an effective remedy for a particular symptom
or disease.

VI. Defective Design
A.

Theory

At the most basic level, a defectively designed product is one
designed in a way that is not suitable or safe for its intended purpose.
Courts have articulated various criteria and tests for determining
whether a design is defective. Nonetheless, it is generally true that the
tests advanced under theories of strict liability in tort, negligence, and
breach of implied warranty are comparable.298
The Restatement (Second) of Torts § 402A refers to a product that
is “in a defective condition unreasonably dangerous . . . .”299 The term,
“unreasonably dangerous,” has been defined as more dangerous than an
average consumer expects, so risky that a reasonable seller would not
sell the product, or that the risks of the product’s design outweigh its
benefits.300
Courts have chosen consumer expectations,301 risk-utility analysis,302
or both, to ground strict tort liability.303 In Arizona, for example, strict
reliability requires three premises: (1) the product is “in a defective
condition unreasonably dangerous;” (2) the product does not perform
298. See generally Kristine C. Karnezis, Annotation, Products Liability:
Modern Cases Determining Whether Product is Defectively Designed, 96
A.L.R.3d 22 (2017).
299. RESTATEMENT (SECOND) OF TORTS § 395 (AM. L. INST. 1965).
300. Id.
301. See Aaron D. Twerski, From Risk-Utility to Consumer Expectations:
Enhancing the Role of Judicial Screening in Product Liability Litigation,
11 HOFSTRA L. REV. 861, 895-96 (1983).
302. Id.
303. Id.
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as safely as expected by an ordinary consumer when used in a
reasonable or intended fashion; and (3) the design’s risks outweigh its
benefits.304 Comment g of the Restatement (Second) of Torts § 402A is
incorporated as part of the premise: “[t]he rule stated in this Section
applies only where the product is, at the time it leaves the seller’s hands,
in a condition not contemplated by the ultimate consumer, which will
be unreasonably dangerous to him.”305 On the other hand, a negligence
claim starts with the contention that the product’s design does not meet
its intended purpose306 and the manufacturer has not made the product
safe for its intended uses by taking reasonable care in the product’s
design.307 Regardless of whether the claim is filed under theories of strict
tort liability or negligence, Arizona holds that when the user knows of
the dangers, when the dangers are very obvious, or when the dangers
are widely known, the manufacturer is not liable for those dangers.308
Cases asserting a breach of the implied warranty of merchantability
either: (1) use a generalized test for defective design, such as fitness for
the product’s intended purpose; or (2) consider the product’s safety for
its intended use as a measure of fitness.309
The decision of how to characterize a pharma-pseudical, such as
medical marijuana, involves a battle between the Second and Third
Restatements of Torts and their respective comments. Regarding
prescription drugs, the Second Restatement states that manufacturers
should not be subject to strict tort liability for drugs that have
therapeutic benefit but are also “unavoidably unsafe.”310 In the Third
Restatement, a product is defective when a reasonable alternative
design would have limited or eliminated the foreseeable risk inherent in
the use of the product.311 The most radical approach is taken by the
Third Restatement, which limits design defects to those drugs that no
reasonable health care provider, knowing the foreseeable risks and
benefits, would prescribe for any patient.312 In other words, if a drug is

304. Stilwell v. Smith & Nephew, Inc., 482 F.3d 1187, 1194 (9th Cir. 2007)
(Internal citations omitted).
305. RESTATEMENT (SECOND) OF TORTS § 402(A) (comment g defective
condition) (AM. L. INST. 1979).
306. Stilwell, 482 F.3d at 1194.
307. RESTATEMENT (SECOND) OF TORTS § 395 (AM. L. INST. 1965); See Mather
v. Caterpillar Tractor Corp., 23 Ariz. App. 409 (1975).
308. Mather, 23 Ariz. App. at 412.
309. Products Liability: Modern Cases Determining Whether Product is
Defectively Designed, 96 A.L.R.3d 22 (1979).
310. RESTATEMENT (SECOND) OF TORTS § 402A cmt. k (AM. L. INST. 1965).
311. RESTATEMENT (THIRD) OF TORTS § 2(b) (AM. L. INST. 1977).
312. RESTATEMENT (THIRD)
INST. 1998).
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prescribed by a reasonable healthcare provider for any reasonable
indication, it is not defectively designed.
Certain basic facts must be known to determine whether a medical
cannabis edible is defective. Are cannabis edibles useful for any medical
purpose? If so, what are the indications? What are the risks? Are edibles
safe, unavoidably unsafe with a therapeutic benefit, or unreasonably
dangerous? Would a reasonable alternative design diminish the
foreseeable risk?
B.

Defective Design in Medical Marijuana

Marijuana-infused edibles are likely to be the main source of
products liability litigation in medical marijuana. For edibles to be safe,
they must have a reasonable concentration of THC that is uniform from
one batch of edibles to another. Proper product sampling techniques
and accurate testing by high quality laboratories are required. The
product must also have a portion size that is reasonable relative to the
total dose of THC in the product.
Stoney Bakes produces a double chocolate chip cookie. It resembles
a true home-baked cookie, and has received five-star rave reviews on
the Leafly website.313 The cookie is described as “fresh and moist,” “very
tasty,” and “A+ top quality.”314 One user, plagued by untreatable,
bimonthly migraine headaches, reports obtaining complete relief from a
headache within two hours of eating the cookie.315 On its face, the cookie
appears to be a very well-made and successful product; however, it has
a very serious design defect that makes it unreasonably unsafe.
The suggested THC dose in an edible for a new cannabis user is
five milligrams.316 Experienced users often take at least a ten-milligram
dose.317 As in most areas of medicine, the smallest effective dose of

313. 250mg
Double
Chocolate
Chip
Cookie
Reviews,
LEAFLY,
https://www.leafly.com/products/details/stoney-bakes-adivision-ofasfas-genetics-confetti-sugar-cookie/reviews (last visited Sept. 19, 2018)
[hereinafter 250 mg Cookie, LEAFLY].
314. Stoney Bakes, LEAFLY, https://www.leafly.com/products/details/stoneybakes-a-division-of-asfas-genetics-confetti- sugar-cookie/reviews (last
visited Sept. 28, 2018).
315. Id.
316. Part 1, 5 Tips to Safely Dose and Enjoy Cannabis Edibles, LEAFLY,
https://www.leafly.com/news/cannabis-101/5-tips-to-safelydose-andenjoy-cannabis-edibles (last updated Mar. 14, 2018) [hereinafter 5 Tips,
LEAFLY].
317. The THC Dosage Guide: Flower, Edibles, Concentrates and More, KEY
CANNABIS,
https://keytocannabis.com/blogs/cannabis/the-thcTO
dosage-guide-flower-edibles-concentrates-and-more (last visited Oct. 14,
2018).
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medication is preferred because it lessens the number and severity of
side effects.318
A cookie this size is typically eaten all at once. Many people may
even have more than one. The problem with Stoney Bakes’ product is
that one cookie contains 250 milligrams of THC,319 enough THC for
fifty novice users or twenty-five experienced users. To obtain a fivemilligram dose of THC, the cookie must be divided in fifty equal pieces,
a virtual impossibility. Then, just one piece can be consumed, and I’ll
“bet you can’t eat just one.”320 Because it is highly likely that a novice
consumer of this THC-infused cookie will overdose on THC based on
the minuscule serving size, the cookie is in a defective condition and
unreasonably dangerous. A normal consumer would not anticipate the
need to cut a cookie into fifty equal pieces and eat just one to obtain
the correct dose; therefore, the cookie is not as safe as an ordinary
consumer would expect it to be when used in a reasonable fashion.
Finally, the design’s risks greatly outweigh its benefits. A safer
alternative design is simple – put less THC in the cookie. For example,
the cookie could be made with a single dose of THC, perhaps 2.5
milligram, 5.0 milligram, or 10.0 milligram cookies, for consumption in
one sitting. Instead of charging $20 for a 250 milligram cookie,321 the
retailer could charge $5 for a 10.0 milligram cookie. Profit margins
would skyrocket and liability would tumble. In other words,
individually wrapped servings with proper dosages would eliminate the
design defect and are eminently feasibly.
Producers can alter Cannabis sativa plants in various ways and
usually aim for high THC concentration hybrids.322 A consumer could
ground a defective design claim on the fact that the design of marijuana
plants or its derivatives created to additional health risks, made the
product more dangerous in some way, or increased its addiction
potential.
The potency of cannabis has changed dramatically over the past
two decades. The THC concentration of 38,681 samples of marijuana
confiscated by the DEA between 1995-2014 was assayed in a 2016
318. James P. McCormack et al., Is Bigger Better? An Argument for Very
Low Starting Doses, 183 CANADIAN. MED. ASS’N. J. 65 (2011).
319. 250 mg Double Chocolate Chip Cookie, LEAFLY, https://www.leafly.com
/products/details/stoney-bakes-a-division-of-asfas-genetics-confettisugar-cookie (last visited Sept. 14, 2018).
320. Eben Shapiro, The Media Business: Advertising; Crisper Chips, Fresh
Slogans, N.Y. TIMES, (May 8, 1992) https://www.nytimes.com
/1992/05/08/business/the-media-business-advertising-crisper-chipsfresh-slogans.html.
321. 250 mg Cookie, LEAFLY, supra note 313.
322. David McLeod, A New Crop of Marijuana Geneticists Sets Out to Build
Better Weed, WIRED (Apr. 20, 2016, 7:00 AM), https://www.wired.com
/2016/04/the-science-of-marijuana/.

267

Health Matrix·Volume 29·Issue 1·2019
High Times Ahead: Products Liability in Medical Marijuana

study.323 Two trends were evident. First, the average potency of THC
increased linearly from four percent in 1995 to twelve percent in 2014,
a three-fold increase.324 Second, the concentration of CBD dropped from
0.28% in 1995 to 0.15% in 2014.325 The increased THC potency is
desirable for growers and retailers because consumers will pay more for
higher concentrations of THC that engender greater euphoric effects for
the same amount ingested (or smoked).326
The effects of CBD have been reviewed at length.327 In many ways,
CBD is the antithesis of THC. CBD inhibits the reuptake and
degradation of anandamide, an endogenous cannabinoid, while THC
results in relative depletion of anandamide. Anandamide depletion
causes the psychotomimetic effects of THC.328 CBD exerts agonist
activity at the 5-hydroxytryptamine receptors (serotonin receptors),
mediating its anxiolytic, antidepressant, and precognitive effects.329
While CBD has salutary effects in the clinical setting,330 THC use is
associated with anxiety, mood disturbances, sleep disturbance,
depression, mania, and schizophrenia. 331
Medical marijuana that is designed to maximize THC and minimize
CBD may be defectively designed for therapeutic purposes. It is not fit
for its intended purpose because it may promote, rather than treat, a
symptom or a disease. High THC concentration also makes marijuana
more addictive,332 engendering more frequent and intensive use. An
323. Mahmoud A. ElSohly et al., Changes in Cannabis Potency Over the Last
2 Decades (1995-2014): Analysis of Current Date in the United States, 79
BIOLOGICAL PSYCHIATRY 613, 614-616 (2016).
324. Id.
325. Id.
326. Mike Pizzo, If You’re Buying Your Weed Solely on the THC Level, You’re
Doing it Wrong, MEDIUM (May 5, 2017), https://medium.com/
trykecultivator/if-youre-buying-your-weed-solely-based-on-the-thc-levelyou-re-doing-it-wrong-ec5422d4ddfd.
327. Rong et al., supra note 15.
328. Id. at 214.
329. Id.
330. Id. at 215.
331. Amber L. Bahorik et al., Patters of Marijuana Use Among Psychiatry
Patients with Depression and its Impact on Recovery, 213 J. AFFECTIVE
DISORDERS 168, 170 (2017); Keren I. Bolla et al., Sleep Disturbance in
Heavy Marijuana Users, 31 SLEEP 901, 906 (2008); Nora D. Volkow et
at., Decreased Dopamine Brain Reactivity in Marijuana Abusers is
Associated with Negative Emotionality and Addiction Severity, 111 Proc.
of the Nat’l Acad. Sciences of the U.S. E3149, E3155 (2014); Wayne Hall
& Louisa Degenhardt, Cannabis Use and the Risk of Developing a
Psychotic Disorder, 7 WORLD PSYCHIATRY 68, 70 (2008).
332. Marijuana, NAT’L INST. DRUG ABUSE, https://www.drugabuse.gov/
publications/drugfacts/marijuana.
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ordinary consumer would not reasonably anticipate that medical
marijuana would make his or her symptom or disease worse and foster
addiction. An alternative design (low THC/high CBD) is safer,
imminently feasible, less costly, and likely to eliminate many of the
foreseeable risks of high THC edibles.
Defective design claims will arise in cannabis production. At
present, numerous edibles are unreasonably dangerous because they
contain concentrations of THC that will overdose the naïve or average
user. In addition, production of edibles high in THC and low in CBD
tends to increase the toxicity of cannabis while lowering its medicinal
utility.

VII. Failure to Warn
A.

General Considerations

Products may be defective despite flawless design and precise
manufacture. When a product becomes dangerous due to a lack of
adequate instructions or warnings, the “failure to warn” makes the
product defective.333 “[M]anufacturers have a duty to warn consumers
about the hazards inherent in their products,”334 including their safe
and proper use. The duty to warn extends to “latent dangers resulting
from foreseeable uses” of the product that the manufacturer knew, or
should have known, and to unintended uses of the product that were
reasonably foreseeable.335 In general, there is no duty to warn of obvious
dangers.
The Restatement (Third) of Torts also characterizes warning
defects:
§ 2 Categories of Product Defect
A product is defective when, at the time of sale or distribution, it
contains a manufacturing defect, is defective in design, or is
defective because of inadequate instructions or warnings. A
product:
....
(c) is defective because of inadequate instructions or warnings
when the foreseeable risks of harm posed by the product could
have been reduced or avoided by the provision of reasonable
instructions or warnings by the seller or other distributor, or a
predecessor in the commercial chain of distribution, and the

333. Barker v. Lull Eng’g Co., 573 P.2d 443, 452 (Cal. 1978).
334. Taylor v. Elliot Turbomachinery Co., 171 Cal. App. 4th 564, 577 (2009).
335. Liriano v. Hobart Corp., 92 N.Y.2d 232, 237 (N.Y. 1998).
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omission of the instructions or warnings renders the product not
reasonably safe.336

In Arizona, “product liability action” is defined as:
any action brought against a manufacturer or seller of a product
for damages for bodily injury, death or property damage caused
by or resulting from . . . the failure to warn or protect against a
danger or hazard in the use or misuse of the product or the failure
to provide proper instructions for the use or consumption of any
product.337

A complaint alleging that a manufacturer failed to provide
adequate warnings of a product’s dangers may be brought under at
least three legal doctrines: strict liability, implied warranty, and
negligence.338 The failure to warn may be viewed as negligent under a
negligence theory, as the defect itself under strict liability in tort, or as
a breach of the warranty of merchantability since the product is not fit
for ordinary uses without the warning.
B.

Warnings About Pharmaceuticals

Earlier, this article described how prescription drugs are different
from other products.339 Prescription drugs are even described as
“unavoidably unsafe products.”340 However, they are not considered
defective or unreasonably dangerous when accompanied by proper
directions for use and adequate warnings of potential side effects.341 A
pharmaceutical manufacturer has a duty to warn of potential side
effects of a medication that are known or knowable in view of the
medical and scientific knowledge at the time of manufacture.342 Because
pharmaceutical manufacturers receive constant feedback about drug

336. RESTATEMENT (THIRD) OF TORTS § 2(c) (AM. LAW INST. 1977).
337. Ariz. Rev. Stat. Ann. § 12-681(5) (2018).
338. David G. Epstein, Products Liability: Defenses Based on Plaintiff’s
Conduct, 1968 UTAH L. REV. 267, 268 (1968).
339. See discussion supra note Part III.
340. RESTATEMENT (SECOND) OF TORTS § 402A cmt. k (AM. LAW INST. 1965).
341. Aaron v. Wyeth, No. 2:07cv927, 2010 WL 653984, at *5, *6 (W.D. Pa.
Feb. 19, 2010); ELLEN FLANNERY & SANDFORD N. GREENBERG, WOMEN
AND HEALTH RESEARCH: ETHICAL AND LEGAL ISSUES OF INCLUDING
WOMEN IN CLINICAL STUDIES VOL. 2 93 (Anna C. Mastroianni et al. eds.,
1994).
342. Muilenberg v. Upjohn Co., 320 N.W.2d 316, 331 (Mich. Ct. App. 1982).
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side effects and dangers from multiple sources, they have a continuing
duty to warn.343
In a negligence action, a drug manufacturer’s liability is based
on its duty. In other words, these actions depend on whether a duty to
warn existed, what the nature of the duty was, whether there was a
breach of that duty, and whether the breach of the duty proximately
caused the plaintiff’s injury.344
A warning is sufficient when it is reasonable.345 A reasonable
warning must: (1) describe the extent of the danger; (2) convey the
seriousness of the danger; (3) alert a prudent health care practitioner
to the danger; and (4) present the information in a satisfactory
manner.346 Warnings about specific drugs should include: (1) harmful
propensities of the drug known (or that should be known) to the
manufacturer; (2) side effects; (3) dangerous interactions with other
drugs; and (4) potential exacerbation of other medical conditions by
the drug.347 A manufacturer must possess the knowledge of an expert in
the relevant area of medicine and keep current with the scientific
literature and discoveries in the field.348 The duty to warn extends to
the risks the pharmaceutical manufacturer discovers from continuous
monitoring of drug safety.349
In strict liability actions under the Restatement (Second) of Torts,
or under products liability in the Restatement (Third) of Torts,
a drug manufacturer’s failure to adequately warn of side effects
associated with a prescription drug renders the drug ”unreasonably
dangerous,” or “not reasonably safe” and therefore defective.350 Strict
tort liability is not concerned with notions of culpability.351 Unlike
343. The duty to warn may vary by state requirements. RESTATEMENT (THIRD)
OF TORTS: PRODUCTS LIABILITY §10(a-b) (AM. LAW INST. 1997); Kenneth
Ross, Post-Sale Duty to Warn: A Critical Cause of Action, 27 WM. MITCHELL
L. REV. 339, 346 (2000); Brian J. Hunt, Is the Door Opening for Plaintiffs?, FOR
THE DEFENSE 60, 61 (2014).
344. See Muilenberg v. Upjohn Co., 320 N.W.2d at 365.
345. Id.
346. Ehlis v. Shire Richwood, Inc., 233 F. Supp. 2d 1189, 1196 (D. N.D. 2002).
347. Weilbrenner v. Teva Pharmaceuticals, 696 F. Supp. 2d 1329, 1333-40
(M.D. Ga. 2010).
348. Braun v. Roux Distrib. Co., 312 S.W.2d 758, 763 (Mo. 1958); Krug v.
Sterling Drug, Inc., 416 S.W.2d 143, 149 (Mo. 1967).
349. Brittany L. Raposa, Caveat Emptor: Protecting Inexpensive Generic
Drugs at the Expense of Patient Safety, 27 HEALTH LAW. 28, 29 (2015).
350. RESTATEMENT (SECOND) OF TORTS § 402A (AM. LAW INST. 1965);
RESTATEMENT (THIRD) OF TORTS: PRODUCTS LIABILITY § 6 (AM. LAW
INST. 1997).
351. Strict Liability, JUSTIA, https://www.justia.com/injury/negligencetheory/strict-liability/ (last visited Dec. 18, 2018).
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negligence, strict liability for failure to warn extends beyond the
manufacturer to all entities in the supply chain.352
In implied warranty actions, drug manufacturer liability may be
similarly analyzed in terms of a duty to warn;353 however, it has also
been suggested that the implied warranty of merchantability does not
apply to prescription drugs because they are characterized as
unavoidably unsafe ab initio.354
In failure to warn cases involving unavoidably dangerous drugs, the
standards for liability under negligence and strict liability are very
similar or even “functional equivalents.”355 Regardless of the claim or
claims asserted in a failure to warn case, the basic factual elements that
must be proven are fundamentally the same.356 In Werner, the Fourth
Circuit observed that any distinction between negligence and strict
liability diminishes considerably in failure to warn cases.357 Whether the
defendant exercised due care in formulating the warning is the issue
under negligence,358 while under strict liability theory, the issue is
whether an inadequate warning created an unreasonably dangerous
product.359 The salient question is whether the warning was adequate.
If the manufacturer provided an adequate warning, Restatement
(Second) of Torts § 402A, comment k, makes it clear that
a drug manufacturer is not strictly liable for injuries caused by an
unavoidably dangerous prescription drug.
A warning is only adequate when it is directed at the correct party.
In Part III, the Learned Intermediary Doctrine and its three recognized
exceptions were discussed (minor children, direct marketing, and
patient-driven choice). One example of an exception is mass vaccination
cases where vaccines were marketed directly to consumers. The Ninth
Circuit has held that the manufacturer knew that each individual
patient would not have been evaluated and counseled by a physician in
advance of the immunization; therefore, the usual risks and benefits of

352. Cf. 8 Am. Jur. Proof of Facts 3d 547 (last updated 2018); see generally
Randy R. Koenders, Annotation, Products Liability: Liability of
Manufacturer or Seller as Affected by Failure of Subsequent Party in
Distribution Chain to Remedy or Warn Against Defect of Which He
Knew, 45 A.L.R. Fed. 4th Art. 777 (1986).
353. Reyes v. Wyeth Laboratories, 498 F.2d 1264, 1276 (5th Cir. 1974).
354. Taylor v. Danek Medical, Inc., No. Civ.A. 95–7232, 1998 WL 962062 at
*7, *13-14 (E.D. Pa. Dec. 29, 1998).
355. Feldman v. Lederle Laboratories, 479 A.2d 374, 386 (N.J. 1984).
356. Cf. 8 Am. Jur. Proof of Facts 3d 547 (last updated 2018).
357. Werner v. Upjohn Co., Inc., 628 F.2d 848, 858 (4th Cir. 1980).
358. Id. at 858.
359. Id. at 857.
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treatment would not have been considered or discussed.360 In that
circumstance, it was the responsibility of the manufacturer to ensure
that vaccination warnings reached the consumer either directly or
through the purchaser of the vaccine (i.e., the vaccinator).361 The Court
equated this to over-the-counter drugs where warnings can be given
with proper labeling, posters, and advertisements.362
In the second exception, a manufacturer is also required to directly
warn a consumer about a drug’s dangerous risks when that drug is
directly promoted and marketed to consumers through advertising. In
Perez v. Wyeth Labs, Inc., the Supreme Court of New Jersey held that
the Learned Intermediary Doctrine was inapplicable when
pharmaceuticals were directly marketed to consumers, and
manufacturers were responsible to directly warn patients of a drug’s
dangerous propensities. 363 If warnings were inadequate, manufacturers
were subject to consumer claims for failure to warn.364
Another exception concerned the long-term use of birth control
pills. When a woman selects a contraceptive, the physician often plays
a peripheral or secondary role in the selection.365 The choice is typically
based on patient preference rather than the physician’s comprehensive
discussion of the risks, benefits, and alternatives of any therapeutic
modality.366 In that regard, the McDonald court held that a birth
control pill manufacturer had a duty to directly warn consumers of the
risks of its product, also noting that direct warnings were eminently
feasible.367
C.

Failure to Warn and Adequately Label Marijuana Products

Professor David Owen developed a helpful rubric for evaluating the
adequacy of warnings based on content and form.368 Owen refers to
content as, “Substantive Adequacy,” and relates it to the clarity and
completeness of the description of a product’s specific risks.369 The form

360. Davis v. Wyeth Laboratories, Inc., 399 F.2d 121 (9th Cir. 1968).
361. See id. at 131.
362. Id.
363. Perez v. Wyeth Laboratories Inc., 734 A.2d 1245 (N.J. Sup. Ct. 1999).
364. Id. at 1252.
365. See Christine Dehlendorf et al., Women’s Preferences for Contraceptive
Counseling and Decision Making, HHS PUBLIC ACCESS (Nov. 21, 2012),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026257/.
366. Id.
367. MacDonald v. Ortho Pharm. Corp., 475 N.E.2d 65, 70 (Mass. 1985).
368. DAVID G. OWEN, PRODUCTS LIABILITY
Academic Publishing, 9th ed., 2015).
369. Id. at 285-286.
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of the warning is its “Procedural Adequacy,” describing the mode of
conveyance of the message.370
While the primary focus of this paper is on medical marijuana, it is
at least as important that users of recreational marijuana be provided
with appropriate and effective warnings and product labeling.
Consumers generally understand that there are potential risks and side
effects associated with the use of medications. Consumers may not
appreciate the risks of using recreational marijuana, especially when the
edible form of the product resembles common products and sizes that
have been in the public domain for decades. Furthermore, in most
states, medical marijuana users do not receive more product
information than a purchaser for recreational purposes would.371
The scope of the duty to warn with respect to medical marijuana
has not been defined or articulated because the industry is still in its
infancy, and clinical trials in the United States are very limited.372
Nonetheless, failure to warn will likely be the most significant area of
cannabis products liability litigation. All participants in the cannabis
supply chain should consider what extent of disclosure is necessary to
limit failure to warn liability.
1. Kirk v. Nutritional Elements

One medical marijuana case, Kirk v. Nutritional Elements, is being
litigated predominantly on a theory of failure to warn.373 It is a sad case,
but its themes are instructive. Kristine and Richard Kirk, a married
couple in Denver, had three sons, ages seven, eleven, and thirteen.374 In
early 2014, Richard purchased a THC-infused edible, Karma Kandy

370. Id. at 286.
371. John M. Malouff et al., Cannabis Users’ Recommended Warnings for
Packages of Legally Sold Cannabis: An Australia-Centered Study, 1
CANNABIS & CANNABINOID RESEARCH 239, 240 (2016). See 4 Differences
When Serving Medical Marijuana Patients vs. Recreational Customers,
INDICAONLINE (May 25, 2018), https://indicaonline.com/blog/4differences-serving-medical-marijuana-patients-vs-recreationalcustomers/.
372. Israel is the international leader in cannabis research with 110 active
clinical trials. See Yardena Schwartz, The Holy Land of Medical
Marijuana, U.S. NEWS (Apr. 11, 2017, 11:04 AM), https://www.
usnews.com/news/best-countries/articles/2017-04-11/israel-is-a-globalleader-in-marijuana-research.
373. Kirk v. Nutritional Elements, Inc., No. 2016CV31310 (2d Dist. Colo. filed
May 9, 2016).
374. See Plaintiff’s First Amended Complaint and Jury Demand at 3, Kirk v.
Nutritional Elements, Inc., No. 16CV31310 (2d Colo. May 9, 2016).
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Orange Ginger, from Nutritional Elements.375 The product was
packaged, sold, and distributed by Gaia’s Garden.376 It has been
debated whether Richard purchased the edible to treat his back pain or
whether it was for recreational use.377
The product is described as a “delectable taffy”378 containing a “101
milligram hybrid THC with Tears of Phoenix hash oil infused for a very
high CBD concentrate.”379 The packaging did not contain any
instructions about proper consumption or use.380 Specifically, there was
no information about how much to take, whether it should be taken
with food or drink, or how long the product required to take effect.
There were no warnings about the possibility of an overdose or how to
manage an overdose if it were to occur.381 No other printed literature
was included with the purchase.382 Plaintiff’s counsel pointed out that
there were more warnings and instructions on toothpaste, chewing gum,
hand cream, and dog treats.383

375. Emma Gannon, Insurer Refuses to Cover Marijuana Candy Murder,
COURTHOUSE NEWS SERV. (May 8, 2017), https://www.courthousenews
.com/insurer-refuses-cover-marijuana-candy-murder/; Bobbi Sheldon,
Allison Sylte & Anastasiya Bolton, Man, High on Pot Candy, Get 30
Years Prison for Killing Wife, USA TODAY, https://www.usatoday.
com/story/news/nation-now/2017/04/07/husband-killed-wife-pot-candy
/100190066/ (last updated Apr. 7, 2017).
376. Gannon, supra note 375.
377. Richard Kirk had been prescribed opiates for his back pain, but his blood
test for opiates was negative immediately after the homicide. Denver Man
Who Said Marijuana Made Him Kill His Wife Gets 30 Years, NBC NEWS
(Apr. 7, 2017, 8:04 PM), https://www.nbcnews.com/news/usnews/denver-man-who-said-marijuana-made-him-kill-his-wife-n744056.
378. Karma Kandy, GAIA GARDEN, http://gaias.atwebpages.com/product
/karma-kandy/ (last visited Jan. 5, 2019).
379. Gaia’s Garden Karma Kandy, MMJ MENU, https://mmjmenu.com
/dispensaries/1313/menus/1313/menu_items/414021 (last visited Oct.
19, 2018).
380. David Kelly, He Got High and Killed His Wife. A Lawsuit Claims Edible
Marijuana is to Blame, L.A. TIMES (June 1, 2016, 3:00 AM),
http://www.latimes.com/nation/la-na-cannabis-homicide-20160531snap-story.html.
381. Gaia’s Garden Karma Kandy – Orange Ginger – 101mg, MMJ MENU,
https://mmjmenu.com/dispensaries/1313/menus/1313/menu_items/414
021 (last visited Oct. 20, 2018).
382. Plaintiff’s First Amended Complaint and Jury Demand, Kirk v.
Nutritional Elements, Inc., No. 16CV31310 (2d Colo. May 9, 2016).
383. Id.
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Figure 3. Kandy Karma Orange Ginger384

By its appearance, the Karma Kandy Orange Ginger taffy
resembles a caramel-colored Tootsie Roll. Richard Kirk bought a
Karma Kandy like the one shown above, weighing 10 grams.385 For
reference, the Tootsie Roll “Midgee” shown below weighs 6.7 grams.386
A single serving of Tootsie Rolls is six Midgees weighing 40 grams.387

Figure 4. Tootsie Roll Midgee388

The Karma Kandy contains 101 milligrams of THC.389 According
to Leafly, the world’s largest cannabis information resource, the
“standard dose” according to Colorado’s edibles dosing guidelines is ten
milligrams, “but a cannabis newbie or low-tolerance consumer should
384. MMJ MENU, supra note 381.
385. Plaintiffs’ First Amended Complaint and Jury Demand at 7, Kirk v.
Nutritional Elements, Inc., No. 16-CV-31310 (2d Colo. May 9, 2016).
386. Tootsie Roll, SELF NUTRITION DATA, http://nutritiondata.self.com
/facts/sweets/8014/2 (last visited Oct. 2, 2018).
387. Id.
https://pixabay.com/en/chocolate-candy-sugar-sweet388. PIXABAY,
2202140/ (last visited Dec. 14, 2018).
389. Louise Boyle & Ashley Collman, Did this Legal Marijuana-Laced Candy
Called ‘Karma’ Make a Husband Hallucinate and Shoot His Wife?, DAILY
MAIL,
https://www.dailymail.co.uk/news/article-2607372/Did-legalmarijuana-laced-candy-make-man-hallucinate-shoot-wife.html
(last
updated Apr. 18, 2014).
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start with half of that.”390 In other words, a regular cannabis user would
eat one-tenth of one piece of Karma Kandy, and a cannabis-naïve user
should start with one-twentieth of one piece of Karma Kandy. For
comparison purposes, one-twentieth of a Karma Kandy is equivalent to
one-fourteenth of a Tootsie Roll Midgee. It is difficult to imagine
cutting a Tootsie Roll Midgee into fourteen equal pieces, each weighing
0.5 gm, and eating just one. Richard Kirk was cannabis-naïve and
should have eaten one-twentieth of the piece of Karma Kandy taffy.
Instead, he consumed the entire piece, 101 milligrams of THC, at one
time.391
Richard reportedly became delirious, paranoid, and psychotic after
consuming the Karma Kandy.392 Kristine called 911 at 9:30 p.m.,
relating to the operator that Richard was delusional and actively
hallucinating, and the children were terrified.393 He rambled about the
end of the world and asked Kristine and the children to kill him.394
While Kristine spoke to the 911 operator, Richard shot her in the head
with his revolver, killing her instantly.395 Fortunately, the children
escaped.396 Police officers arrived on the scene and took Richard into
custody.397
A professor of medicine at Johns Hopkins opined that Richard
suffered an acute psychotic reaction from a cannabis overdose.398 A
forensic psychiatrist concluded that acute intoxication induced
Richard’s cognitive distortions, especially in view of the fact that his
personality profile was non-violent and non-aggressive.399
A failure to warn suit was filed against the manufacturer and the
dispensary under theories of strict liability in tort and negligence.400
Claims were also filed under strict liability for misrepresentation against
the entities and negligence against Richard.401 In February 2017,

390. See generally 5 Tips, LEAFLY, supra note 316.
391. Plaintiffs’ First Amended Complaint and Jury Demand at 7, Kirk v.
Nutritional Elements, Inc., No. 16-CV-31310 (2d Colo. May 9, 2016).
392. Id. at 5.
393. Id.
394. Id.
395. Id. at 6-7.
396. Id. at 5.
397. Id. at 7.
398. Id. at 19.
399. Id. at 18-19.
400. Id. at 20-21.
401. Id. at 22-23.
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Richard pled guilty to second-degree murder and was sentenced to
thirty years in prison.402 The civil case is pending.403
2. One Candy Bar: Sixteen Servings

Maureen Dowd, a well-known columnist for The New York Times,
reported her own frightening experience with THC-infused edibles in
2014.404 Dowd purchased a THC-infused chocolate caramel bar similar
to one of her childhood favorites. She took a few tiny bites, felt nothing,
and took a few more.405 Just over an hour later, Dowd developed a
hallucinatory and paranoid state of mind.406 Initially, Dowd thought she
had died, but no one would tell her.407 It was not until the next morning
that the effects began to subside.408 In preparation for the article, she
interviewed a medical consultant at the dispensary. One chocolate
caramel bar represented sixteen servings for novice users.409 The bar
was not labeled with dosage information, and no one at the dispensary
warned her about the delay in effect of the edible or the possibility of
overdosing.410
D.

Suggestions for Reasonable Packaging and Verbal Warnings

Kirk and Dowd are examples of the critical nature of dosage
warnings, even for recreational users. Moreover, there are no additional
protections or legal requirements for dosage warnings on products
marketed to medical marijuana patients. Patients should start with low
THC dosages and gradually increase until the desired effect is achieved
without significant side effects. Certifying physicians could discuss
dosages, but there is a paucity of medical literature or continuing
medical education on cannabis therapeutics. Dispensary consultants
should be required to discuss dosages. Most dispensary workers have

402. Noelle Phillips, Richard Kirk Sentenced to 30 Years in Prison in 2014
Observatory Park Slaying of his Wife, DENVER POST (Apr. 8, 2017, 12:12
PM),
https://www.denverpost.com/2017/04/07/richard-kirk-2014observatory-park-wife- homicide-sentencing/.
403. Id.
404. Maureen Dowd, Don’t Harsh Our Mellow, Dude, N.Y. TIMES (June 3,
2014), https://www.nytimes.com/2014/06/04/opinion/dowd-dont-harshour-mellow-dude.html.
405. Id.
406. Id.
407. Id.
408. Id.
409. Id.
410. Id.
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personal experience with cannabis,411 which could be helpful to
customers with questions or concerns. Beginning users should be told
to start with 2.5 milligrams and not exceed 5.0 milligrams of THC;
more experienced users may be advised that it is safe to increase dosage
to 10.0 milligrams. Patients should be advised not to take cannabis
edibles on an empty stomach because absorption is too rapid. Users
should be cautioned about the time delay in experiencing the effect of
the edible (up to two hours) and should be discouraged from consuming
additional edibles before that time to prevent overdosing.
Verbal instructions alone about cannabis use are insufficient. At a
minimum, dosage instructions and warnings should appear on the
product label in a reasonable size font. In addition, it would be prudent
to give the patient the equivalent of a pharmaceutical package insert,
albeit one with less technical language. Medical dispensary consultants
ought to be trained to discuss the package insert and document the
date and time of the discussion, just like when getting a prescription
from a pharmacy. The discussion requirement need not be fully
informed consent, but there should be a requirement for the most
important information to be conferred with initial dispensation.
Issues of short-term and long-term known health risks must be
addressed, especially to vulnerable populations. However, the lack of
clarity of the risks in the extant medical literature complicates matters.
The most significant warnings should be given, but by whom? In the
current structure, physicians claim to lack the time and the dispensary
employees lack the knowledge. But, if no one takes the time to warn,
everyone will get sued.
Even without the desired level of clarity, there are certain warnings
that should be de rigueur. The following groups should always be
advised about the potential complications and side effects:


Pregnant women should be warned that cannabis use during
pregnancy predisposes their offspring to be small in stature and
at risk for cognitive dysfunction, inattention, and behavioral
problems. Lactating women must be cautioned that cannabis
metabolites are present in breast milk and their impact on a
newborn is unknown.



Young adults and adolescents should be knowledgeable about
the ongoing cognitive impairments and diminished academic
success associated with cannabis use accompanied by the
increased likelihood of addiction to marijuana, alcohol, and
illicit drugs.

411. Nancy Haug et al., Training and Practices of Cannabis Dispensary Staff,
1.1 CANNABIS & CANNABINOID RES. 244, 247 (2016).
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Persons with mental health issues, such as depression, anxiety,
and bipolar disorder, should be strongly warned about potential
worsening of their condition.



Novice users must be educated about what being “high” is like,
with its attendant euphoria, altered perception, cognitive
impairment, and psychomotor retardation. Unlike recreational
users, the “high” experienced by a medical marijuana user is
often an undesirable side effect. The purpose of medical
marijuana is to increase functionality and comfort without
cognitive and perceptual impairment.

Furthermore, the following should be discussed with every medical
marijuana user:


There are risks to others, particularly the increased likelihood
of accidents and injury while driving or operating heavy
machinery.



What the symptoms of an overdose look or feel like. Users
should be informed that if they develop paranoia, delusions,
and hallucinations, they should seek emergency care and
observation. The phone number to the local poison control
center should be readily available with the dispensed product.



The clear contraindications to cannabis use. For example,
individuals with schizophrenia or with uncontrolled mental
illness should avoid cannabis unless it is used under the care of
a knowledgeable psychiatrist; angina can be exacerbated by
THC; patients allergic to Cannabis sativa or plants within the
same genus should be strongly cautioned.

There are numerous drug interactions that could produce serious
side effects. The following is a list of the most important drugs and the
type of interaction:


Chlorpromazine – requires increased dosage



Clozapine – clozapine level may rise rapidly after THC
cessation



CNS Depressants – increased drowsiness and CNS depression
when THC is combined with alcohol, opioids, sedative
hypnotics,
barbiturates,
benzodiazepines,
buspirone,
antihistamines, muscle relaxants, and others



Disulfiram – possible mania or psychosis
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Hydrocortisone – increased serum cortisol



Indinavir – decreases peak concentration of this drug



Ketoconazole – increases peak THC concentration



MAO Inhibitors – orthostatic hypotension



Phenytoin – phenytoin level may rise rapidly after THC
cessation



Warfarin – THC may enhance anticoagulant effect412
E.

Labeling and Packaging

Proper labeling and packaging can increase safety of use and
mitigate liability. A number of states have promulgated very specific
rules for labeling and packaging of cannabis.413 Products sold in
California are required to have the following comprehensive label on
the product or insert, all in capital letters:

412. COLO. DEP’T PUB. HEALTH & ENV’T, supra note 161, at 40.
413. A State-by-State Guide to Cannabis Packaging and Labeling Laws,
LEAFLY (Sept. 22, 2015), https://www.leafly.com/news/industry/a-stateby-state-guide-to-cannabis-packaging-and- labeling-laws [hereinafter State
Labeling Laws, LEAFLY].
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GOVERNMENT WARNING: THIS PRODUCT CONTAINS
CANNABIS, A SCHEDULE I CONTROLLED SUBSTANCE.
KEEP OUT OF REACH OF CHILDREN AND ANIMALS.
CANNABIS PRODUCTS MAY ONLY BE POSSESSED OR
CONSUMED BY PERSONS 21 YEARS OF AGE OR OLDER
UNLESS THE PERSON IS A QUALIFIED PATIENT. THE
INTOXICATING EFFECTS OF CANNABIS PRODUCTS
MAY BE DELAYED UP TO TWO HOURS. CANNABIS
USE WHILE PREGNANT OR BREASTFEEDING MAY BE
HARMFUL. CONSUMPTION OF CANNABIS PRODUCTS
IMPAIRS YOUR ABILITY TO DRIVE AND OPERATE
MACHINERY. PLEASE USE EXTREME CAUTION. 414

Nevada has adopted a comprehensive system of labeling
requirements for edibles:
Labeling requirements for concentrated cannabis, edible
marijuana products or marijuana-infused products for sale to
medical marijuana dispensary.
1. A facility for the production of edible marijuana products or
marijuana-infused products shall label all concentrated cannabis,
edible marijuana products and marijuana-infused products before
it sells the products to a medical marijuana dispensary and shall
securely affix to the package a label that includes, without
limitation, in legible English:
(a) The name of the medical marijuana establishment and its
medical marijuana establishment registration certificate number;
(b) The production run number;
(c) The date of production;
(d) The date of final testing;
(e) The date on which the product was packaged;
(f) The cannabinoid profile and potency levels and terpenoid
profile as determined by the independent testing laboratory,
which may include the potential total THC but shall not include
any other calculated level of THC;
(g) If the product is perishable, the expiration date;
(h) The total amount of THC measured in milligrams;

414. Cal. Bus. & Prof. Code § 2612(c)(1)(B) (2016).
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(i) A list of all ingredients and all major food allergens as
identified in 21 U.S.C. § 343;
(j) The net weight of the product; and
(k) If concentrated cannabis was added to the product or if the
product consists solely of concentrated cannabis, a disclosure of
the type of extraction process used and any solvent, gas or other
chemical used in the extraction process or any other compound
added to the concentrated cannabis.415

In addition to these labeling requirements, retail products are
required to have additional information and at least six warnings
related to “intoxicating effects,” potential health risks, and appropriate
use of the product.416 There are even guidelines related to the placement,
font, and size of the labels.417
In an effort to prevent overdose and unintended exposure of
children to cannabis, some states require that marijuana edibles be
packaged in single use, single dose, child resistant packages, limited to
between 5.0 and 15.0 milligrams of THC.418 California and Colorado
limit edible dosages to 10.0 milligrams of THC.419 Most states have child
resistant packaging requirements. Oregon’s packaging goes one step
further by specifying packaging that is not attractive to minors.

415. Nev. Rev. Stat. § 453A.509 (2017).
416. Nev. Rev. Stat. § 453A.512 (2017).
417. Nev. Rev. Stat. §§ 453A.509, 512 (2017).
418. State Labeling Laws, LEAFLY, supra note 413.
419. Chris Roberts, California’s New Edibles Limits Will Ban Popular
Products, LEAFLY (Nov. 27, 2017), https://www.leafly.com/news/
industry/californias-new-edibles-limits-will-ban-popular-products.
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Figure 5. Oregon’s Packaging Requirements420

In addition to text, warning symbols have been selected to identify
products as containing marijuana:

Colorado421

Oregon422

Washington423

Figure 6. Warning Symbols from Different States and Cities

420. OR. LIQUOR CONTROL COMM’N, MEDICAL & RECREATIONAL MARIJUANA
PACKAGING AND LABELING GUIDE 3 (Aug. 2016), http://www.oregon.gov/
olcc/marijuana/Documents/Packaging_Labeling/PackagingandLabeling
Guide_V2.pdf.
421. Responsible Use, COLO. MARIJUANA, https://www.colorado.gov/pacific/
marijuana/responsible-use (last visited Oct. 10, 2018).
422. Marijuana and Your Health, OR. HEALTH AUTH., https://www.oregon.gov
/oha/PH/PreventionWellness/marijuana/Pages/symbol.aspx
(last
visited Oct. 10, 2018).
423. Cannabis Packaging and Labeling Resources, Wash St. Liquor & Cannabis
Board, https://lcb.wa.gov/laws/labeling-resources (last visited Oct. 10,
2018).
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To effectively maximize safety and minimize liability, a balance
needs to be struck between too little and too much information. Too
little information leads to poorly informed patients and enhances
liability for marijuana suppliers. If patients are given too much
information, they will probably not read it. The cannabis purveyor will
be less exposed to liability when detailed risks and instructions are
dispensed with the product. My recommendations include the following:
(1) single dose, child resistant packaging; (2) warning labels with
symbols on the product; and (3) a warning and instruction sheet similar
to a pharmaceutical package insert, but written in layperson’s language.

VIII. Youth Marketing of Marijuana
Medical marijuana can be recommended for individuals eighteen
and over, although rare exceptions exist for younger patients.424
Recreational users must be twenty-one.425 Marketing of marijuana in
states that permit recreational use is supposed to be directed to
individuals twenty-one years and older.426 However, in states with
recreational use, medicinal use, or both, marketing is often directed to
the younger Millennials, individuals currently between the ages of
eighteen and twenty-five years.427 The marketing plan appears to be
based on the fact that virtually anyone with a little knowledge and
coaching can qualify for a medical marijuana card.428 It is only necessary
to remember the new four-letter word, “pain.”
The most popular criterion for medical marijuana qualification is
chronic pain.429 Pain is entirely subjective and is hard to prove or
disprove.430 In Arizona, a sizeable and disproportionate number of
Millennials are afflicted with “chronic pain” despite that fact that they
may have no history of a disease process that causes chronic pain and
424. Medical
Marijuana
Age
Requirement,
MARIJUANA
https://www.marijuanadoctors.com/blog/medical-marijuana-agerequirement/ (last visited Oct. 10, 2018).

DRS.,

425. Id.
426. Anna Gorman, In the Age of Legalization, Talking to Kids About
Marijuana Gets Tougher, NPR (Nov. 10, 2009), https://www.npr.org/
sections/health-shots/2017/11/10/563051543/in-the-age-of-legalizationtalking-to-kids-about-marijuana-gets- tougher.
427. Melissa Jenco, Study: Medical Marijuana Advertising Linked to Teen Use,
AAP NEWS (May 18, 2018), http://www.aappublications.org/
news/2018/05/18/marijuanaads051818.
428. See Josh Harkinson, How to Get a Pot Card (Without Really Trying),
MOTHER JONES (Oct. 11, 2010), https://www.motherjones.com/
politics/2010/10/california-medical-marijuana-pot-card/.
429. Hill et al., Cannabis and Pain: A Clinical Review 2.1 CANNABIS &
CANNABINOID RES. 96, 97 (2017).
430. Id.
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have not had a medical evaluation or appropriate testing to determine
the source of the pain.431
In several states, the presence of chronic pain alone is not sufficient;
the pain must be “debilitating.”432 It appears that some medical
marijuana clinics set a very low bar for certification of “debilitated”
individuals. For example, the complaint of back pain lasting more than
six months is considered to be debilitating by some clinics,
notwithstanding the fact that the patient is entirely functional and
without physical limitations.433 The clinics use the catch phrase, “Get
Legal,”434 which appears to roughly translate into: (1) come to the clinic;
(2) get certified; and (3) use marijuana legally.
Medical marijuana clinics frequently advertise in free newspapers
available on college campuses.435 Their appeal to youth is undeniable.
Advertisements contain eye-catching color and layouts.436 The names of
the clinics evoke images of natural or organic products used in a holistic,
patient-focused, and compassionate fashion letter.437 Some clinics
advertise that customers do not need prior medical records; everything
necessary can be done at the visit.438 However, in Arizona, it is almost
certainly true that an individual with “a debilitating medical
431. See, e.g., ARIZ. DEPT’ HEALTH SERV., ARIZONA MEDICAL MARIJUANA
PROGRAM
DECEMBER
2018
MONTHLY
REPORT
(2018),
https://www.azdhs.gov/documents/licensing/medical-marijuana/reports
/2018/2018-dec-monthly-report.pdf; Eli McVey, Chart: Arizona’s Massive
Medical Marijuana Market Keeps Growing, MARIJUANA BUS. DAILY (Feb.
5,
2018),
https://mjbizdaily.com/chart-arizonas-massive-medicalmarijuana-market-keeps-growing/; Britt Hermes, I was a Pot Doctor;
Naturopaths Blowing Smoke with Medical Marijuana, NATUROPATHIC
DIARIES (Dec. 21, 2016), https://www.naturopathicdiaries.com/potdoctor-naturopaths-medical-marijuana/.
432. How to Get a Legal Medical Marijuana Card or Authorization, LEAFLY,
https://www.leafly.com/news/health/qualifying- conditions-for-medicalmarijuana-by-state (last updated Oct. 6, 2018).
433. Chronic Pain Qualifies for Medical Marijuana In Ohio, OHIO MARIJUANA
CARD, https://www.ohiomarijuanacard.com/pain (last visited Jan. 4,
2019).
434. GET LEGAL, http://getlegalarizona.com/ (last visited Oct. 21, 2018).
435. See, e.g. The Holistic Center, METRO, (Oct. 21, 2018),
http://boston.metro.us/html5/reader/production/default.aspx?pubname
=&edid=7e725dc3-7488-4753-8501-.
436. See David K. Israel, 9 Medical Marijuana Ads, MENTAL FLOSS (Mar. 15,
2010), https://mentalfloss.com/article/24200/9-medical- marijuana-ads.
437. The 100 Best Dispensaries, CANNABIS NOW
https://cannabisnow.com/100-best-dispensaries/.

(Mar.

24,

2017),

438. Jonathan Martin, No Medical Records? No Problem. Got My Pot Card
at Hempfest, SEATTLE TIMES (Aug. 20, 2011, 6:28 PM),
https://www.seattletimes.com/seattle-news/no-medical-records-noproblem-got-my-pot-card-at-hempfest/.
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condition,” as defined by A.R.S. § 36-2801(3), would not suffer from a
lack of medical records.439
Colorado has codified the limitations in retail marijuana youth
marketing by adopting the standards of the alcohol industry.440 Retail
marijuana establishments must refrain from television, radio, print,
internet, and pop-up advertising unless the establishment has reliable
evidence that no more than thirty percent of the audience for the
television program, radio broadcast, print publication, or website is
reasonably expected to be under the age of twenty-one.441
RAND researchers442 collected data from 8,200 students enrolled in
grades six through eight (mean age of thirteen years) in California
during 2010 and 2011.443 Twenty-two percent of students reported
seeing an advertisement for medical marijuana services at least once
during a three-month period in 2010.444 The frequency increased to
thirty percent in 2011.445 Adolescents who saw medical marijuana
advertising were more likely to either report using marijuana or to say
they planned to use it in the future.446 The study is significant because
onset of cannabis use during early adolescence has been correlated with
neuropsychological performance deficits, poor school performance, and
concomitant use of illicit drugs.447 RAND recommended regulating
medical marijuana advertisements in the same fashion as alcohol and
tobacco products.448

439. Ariz. Revised Statute § 36-2801(3) (West 2010). Debilitation medical
conditions include: cancer, glaucoma, positive status for human
immunodeficiency virus, acquired immune deficiency syndrome, hepatitis
C, amyotrophic lateral sclerosis, Crohn’s disease, and agitation of
Alzheimer’s disease.
440. Colo. Code Regs. § 212-2 (2018).
441. Id.
442. RAND CORPORATION, https://www.rand.org/about/history.html (last
visited Oct. 21, 2018). Research and Development (RAND) is a nonpartisan corporation that performs research and provides analysis to
inform policy decisions.
443. Elizabeth J. D’Amico et al., Gateway to Curiosity: Medical Marijuana
Ads and Intention and Use During Middle School, 29 PSYCHOLOGY OF
ADDICTIVE BEHAVIORS 613, 614 (2015).
444. Id. at 615.
445. Id.
446. Id.
447. Emily D’Amico, Adolescents Who View Medical Marijuana Advertising
Are More Likely
to Use the Drug, RAND CORPORATION (Jul. 6, 2015), https://www.rand.org
/news/press/2015/07/06.html.
448. Id.
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To make cannabis less appealing to youth, California Senator Ben
Allen introduced Senate Bill 162, which would prohibit marijuana
dispensaries, producers, and growers from advertising their businesses
on clothing, hats, or other promotional merchandise.449 The Bill also
prohibits cannabis advertising within 1,000 feet of a daycare, grade
school, playground, or youth center.450 The legislation is endorsed by
the RAND Drug Policy Research Center and supported by the
American Academy of Pediatrics.451 The Bill has been referred to the
Committee on Appropriations.452
A bill to ban billboard advertising for medical marijuana,
dispensaries, and businesses that promote medical marijuana has been
introduced in Michigan and approved by the Senate Judiciary
Committee in late September 2017.453
Twitter is a social media platform with over 300 million monthly
users.454 With its short messages and photos, it establishes trends and
influences the consumption of goods and services.455 Online magazines
frequently list the most followed and influential cannabis-related

449. Dennis Romero, T-Shirts and Hats Used to Advertise Pot Products Could
Be
Banned, L.A. WEEKLY (June 26, 2017, 6:03 AM),
https://www.laweekly.com/news/california-law-would-ban-somemarijuana-branded-clothing-8361493.
450. S.B. 162, 2017 Leg. Sess. (Cal. 2017).
451. California Bill Seeks to Ban Branded Cannabis Merchandise, COLUM.
NORML (Sept. 3, 2017), http://columbianorml.org/norml-news/
california-bill-seeks-to-ban-branded-cannabis-merchandise/; Michael Kim,
Senate Aims to Protect the Youth of California by Banning the Use of
Branded Merchandise in Cannabis Advertising, CKB VIENNA (Oct. 10,
2017),
https://www.ckbvienna.com/blog/2017/10/31/senate-aims-toprotect-the-youth-of-california-by-banning-the-use-of-brandedmerchandise-in-cannabis-advertising.
452. S.B. 162, 2017 Gen. Assemb., Reg. Sess. (Cal. 2017).
453. Senate Panel OKs Jones Bill to Regulate Medical Marijuana Ads, Senator
Rick Jones (Sept. 27, 2017),
http://www.senatorrickjones.com/senate-panel-oks-jones-bill-tomedical-marijuana-ads/.

regulate-

454. Number of Monthly Active Twitter Users Worldwide, STATSIA,
https://www.statista.com/statistics/282087/number-of- monthly- activetwitter-users/ (last visited Oct. 4, 2018).
455. Id.
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Twitter accounts.456 Weed Tweets, with 1.23 million followers, is
number one.457 High Times Magazine, with 640,000 followers, is
considered a major influencer in the marijuana market.458 Follower age
is not restricted. If the cannabis industry is sending out pro-marijuana
information on Twitter, the followers are subjected to industry
marketing regardless of age.459
Researchers studied the content of tweets and the demographics of
the followers of @stillblazingtho, a pro-marijuana Twitter handle with
over one million followers.460 Eighty-two percent of the comments were
positive about marijuana.461 The majority of followers (seventy-three
percent) were nineteen-years old or younger.462 Because this age
category is highly influenced by social media and tends to establish
patterns of drug use at an early age,463 Twitter has enormous power,
but no restraints, when it comes to advertising marijuana to youth.
Some states may be aggressive in limiting youth marketing of
marijuana while others will be laissez-faire in legislation and
enforcement. Prudent cannabis growers, manufacturers, and dispensers
can take steps to ensure that their advertisements and marketing do
not target youth.
Historically, tobacco companies were sued for improperly directing
their marketing and advertising at youth, exposing young people to
tobacco and tobacco addiction at a young age.464 At present, Juul Labs,

456. Top 10 Twitter Accounts for Cannabis Lovers, ZAMNESIA,
https://www.zamnesia.com/blog-top-10-twitter-accounts-for-cannabislovers-n1694 (last edited Apr. 10, 2018); Top 20 Most Influential
Marijuana Related Twitter Accounts, HOW TO GROW BUD (May 6, 2010),
http://www.howtogrowbud.com/top-20-most-influential-marijuanarelated-twitter-accounts/; George Gott, Weed Twitter Accounts to
Follow, POTENT (2016), https://potent.media/weed-twitter-accounts-tofollow; Jennifer Kregor, Cannabis Industry Social Media Showdown GROUP
(Mar.
5,
2018),
March
2018,
BRIGHTFIELD
https://www.brightfieldgroup.com/post/cannabis- industry-social-mediashowdown-march-2018.
457. ZAMNESIA, supra note 456.
458. Id.
459. Patricia Cavazos-Rehg et al. Characterizing the Followers and Tweets of
a Marijuana-Focused Twitter Handle, 16 J. MED. INTERNET RES. e157,
e157 (2014).
460. Id.
461. Id.
462. Id.
463. Id.
464. Laura Bach, Tobacco Company Marketing to Kids, CAMPAIGN FOR
TOBACCO-FREE KIDS (Apr. 10, 2018), https://www.tobaccofreekids.org/
assets/factsheets/0008.pdf.

289

Health Matrix·Volume 29·Issue 1·2019
High Times Ahead: Products Liability in Medical Marijuana

an e-cigarette manufacturer, is in a nationwide class action.465 The
Plaintiffs allege that Juul marketed its product as safe and targeted
youth at the outset.466 A plaintiff could raise a similar claim against the
marijuana industry - a youth marketing claim - if advertisements or
marketing efforts are directed at youth.

IX. Conclusion
The marijuana industry is in its infancy. Most of the industry’s
energy has been spent on cultivating, manufacturing, and distributing
a profitable product without attracting too much attention from federal
prosecutors. Products liability litigation in medical marijuana is just
starting. It will grow and mature over the next two decades.
Medical marijuana shares characteristics with alcohol, tobacco, and
nutritional supplements, but it is most analogous to pharmaceuticals.
Product liability claims for medical marijuana will most resemble claims
for pharmaceuticals, except that the Learned Intermediary Doctrine
will be minimally applicable. Defective design and failure to warn claims
are the most likely ones to prevail. They will predominantly be
grounded in negligence and strict liability in tort.
At present, damages are difficult to assess because adequate
medical research has not been done. However, it is clear that damages
will be both short term and long term. In the short term, injuries will
be related to an acute overdose with claims filed by consumers and
injured bystanders. The evidence will show that products were
improperly evaluated or inadequately labeled. Injured patients will
prove that they were not instructed in the proper use of cannabis or in
its potential side effects. All participants in the supply chain may be
held liable for these misadventures.
Manufacturers and retailers can effectively mitigate liability in two
ways. First, they can keep current with the latest scientific and medical
information about cannabis and educate or warn their customers
accordingly. Second, they can develop and market safer products. These
include, inter alia, single dose, individually wrapped, edibles sold in
child resistant packaging with CBD to THC ratios that are
therapeutically effective and optimally safe. Liability cannot be
designed or warned away, so insurance will be used to transfer the risk.
I predict that state governments will act to provide safer products
and limit marketing to youth while promoting cannabis research. The
465. Deanna Paul, E-Cigarette Maker Juul Targeted Teens with False Claims
of Safety, Lawsuit Says (July 30, 2018), https://www.washingtonpost
.com/news/to-your-health/wp/2018/07/30/e-cigarette-maker-juultargeted-teens-with-false-claims-of-safety-lawsuitclaims/?noredirect=
on&utm_term=.50e77f2cdac2.
466. Pls.’ Compl., Yannuci v. Juul Labs, No. 1:15cv24186 (S.D. Fla Oct. 10,
2018).
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DEA will either reschedule cannabis into Schedule II, III, or IV of its
own accord or will be forced to by Congress. Medical marijuana will
become accepted by the medical community as further research at home
and abroad establishes its therapeutic efficacy and the critical nature
of the endogenous cannabinoid system in the body’s homeostasis. The
patients, manufacturers, and retailers will greatly benefit from
regulation that will reduce both injury and liability.
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